WO2006012325A1 - Delta-8 desaturase and its use in making polyunsaturated fatty acids - Google Patents
Delta-8 desaturase and its use in making polyunsaturated fatty acids Download PDFInfo
- Publication number
- WO2006012325A1 WO2006012325A1 PCT/US2005/022547 US2005022547W WO2006012325A1 WO 2006012325 A1 WO2006012325 A1 WO 2006012325A1 US 2005022547 W US2005022547 W US 2005022547W WO 2006012325 A1 WO2006012325 A1 WO 2006012325A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- delta
- desaturase
- seq
- gene
- plant
- Prior art date
Links
- 108010022240 delta-8 fatty acid desaturase Proteins 0.000 title claims abstract description 122
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title claims abstract description 104
- 238000004519 manufacturing process Methods 0.000 claims abstract description 84
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 79
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims description 131
- 241000196324 Embryophyta Species 0.000 claims description 121
- 235000010469 Glycine max Nutrition 0.000 claims description 117
- 244000068988 Glycine max Species 0.000 claims description 110
- 238000000034 method Methods 0.000 claims description 83
- 229920001184 polypeptide Polymers 0.000 claims description 51
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 45
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 45
- 235000013305 food Nutrition 0.000 claims description 42
- 241000235015 Yarrowia lipolytica Species 0.000 claims description 41
- 230000001105 regulatory effect Effects 0.000 claims description 40
- 239000002773 nucleotide Substances 0.000 claims description 33
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 32
- 108091033319 polynucleotide Proteins 0.000 claims description 30
- 102000040430 polynucleotide Human genes 0.000 claims description 30
- 239000002157 polynucleotide Substances 0.000 claims description 30
- 241000235013 Yarrowia Species 0.000 claims description 23
- 230000000295 complement effect Effects 0.000 claims description 22
- 108020004511 Recombinant DNA Proteins 0.000 claims description 17
- 230000001131 transforming effect Effects 0.000 claims description 16
- 238000012545 processing Methods 0.000 claims description 12
- 210000005253 yeast cell Anatomy 0.000 claims description 9
- 241000223252 Rhodotorula Species 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 241000219198 Brassica Species 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 229920000742 Cotton Polymers 0.000 claims description 5
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 5
- 235000009973 maize Nutrition 0.000 claims description 5
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 244000020518 Carthamus tinctorius Species 0.000 claims description 4
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 4
- 241000219146 Gossypium Species 0.000 claims description 4
- 244000020551 Helianthus annuus Species 0.000 claims description 4
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 4
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 4
- 240000006240 Linum usitatissimum Species 0.000 claims description 4
- 241001149698 Lipomyces Species 0.000 claims description 4
- 241000223230 Trichosporon Species 0.000 claims description 4
- 241001527609 Cryptococcus Species 0.000 claims description 3
- 241000490645 Yarrowia sp. Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000012634 fragment Substances 0.000 abstract description 97
- 150000007523 nucleic acids Chemical group 0.000 abstract description 33
- 108090000623 proteins and genes Proteins 0.000 description 271
- 230000014509 gene expression Effects 0.000 description 117
- 239000013615 primer Substances 0.000 description 95
- 239000000047 product Substances 0.000 description 87
- 239000013612 plasmid Substances 0.000 description 81
- 239000000194 fatty acid Substances 0.000 description 79
- 235000014113 dietary fatty acids Nutrition 0.000 description 78
- 229930195729 fatty acid Natural products 0.000 description 78
- 150000004665 fatty acids Chemical class 0.000 description 74
- 108020004414 DNA Proteins 0.000 description 68
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 67
- 239000003921 oil Substances 0.000 description 62
- 235000019198 oils Nutrition 0.000 description 62
- 150000001413 amino acids Chemical class 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 50
- 210000002257 embryonic structure Anatomy 0.000 description 46
- 239000013598 vector Substances 0.000 description 46
- 230000015572 biosynthetic process Effects 0.000 description 42
- 230000003321 amplification Effects 0.000 description 41
- 238000003199 nucleic acid amplification method Methods 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 40
- 102000004190 Enzymes Human genes 0.000 description 37
- 108090000790 Enzymes Proteins 0.000 description 37
- 229940088598 enzyme Drugs 0.000 description 37
- 241000195619 Euglena gracilis Species 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 36
- 230000009466 transformation Effects 0.000 description 36
- 108091028043 Nucleic acid sequence Proteins 0.000 description 35
- 108020004999 messenger RNA Proteins 0.000 description 35
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 35
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 33
- 239000013604 expression vector Substances 0.000 description 33
- 239000000758 substrate Substances 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 30
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 30
- 238000003786 synthesis reaction Methods 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 30
- 239000000203 mixture Substances 0.000 description 29
- 108010073542 Delta-5 Fatty Acid Desaturase Proteins 0.000 description 28
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 28
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 28
- 230000037361 pathway Effects 0.000 description 28
- 238000013518 transcription Methods 0.000 description 28
- 230000035897 transcription Effects 0.000 description 28
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 27
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 27
- 241000907999 Mortierella alpina Species 0.000 description 26
- 108050008874 Annexin Proteins 0.000 description 25
- 150000002632 lipids Chemical class 0.000 description 25
- 108091026890 Coding region Proteins 0.000 description 23
- 230000000813 microbial effect Effects 0.000 description 23
- 244000005700 microbiome Species 0.000 description 23
- 229940033080 omega-6 fatty acid Drugs 0.000 description 23
- 102000000412 Annexin Human genes 0.000 description 22
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 22
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 22
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 21
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 21
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 20
- 229910052799 carbon Inorganic materials 0.000 description 20
- 239000007788 liquid Substances 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 229940012843 omega-3 fatty acid Drugs 0.000 description 20
- 230000000392 somatic effect Effects 0.000 description 20
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 210000001161 mammalian embryo Anatomy 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 108010011713 delta-15 desaturase Proteins 0.000 description 17
- 238000013519 translation Methods 0.000 description 17
- 235000013372 meat Nutrition 0.000 description 16
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 108020004705 Codon Proteins 0.000 description 13
- 108010087894 Fatty acid desaturases Proteins 0.000 description 13
- 238000009825 accumulation Methods 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 239000000543 intermediate Substances 0.000 description 13
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 12
- 230000000692 anti-sense effect Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 235000012424 soybean oil Nutrition 0.000 description 12
- 239000003549 soybean oil Substances 0.000 description 12
- 108700010070 Codon Usage Proteins 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 238000005984 hydrogenation reaction Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108010075530 Kunitz Soybean Trypsin Inhibitor Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 235000013351 cheese Nutrition 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 108010083391 glycinin Proteins 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 238000004114 suspension culture Methods 0.000 description 10
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 9
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 9
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 9
- 102100034543 Fatty acid desaturase 3 Human genes 0.000 description 9
- 108700037728 Glycine max beta-conglycinin Proteins 0.000 description 9
- 239000005642 Oleic acid Substances 0.000 description 9
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 239000006227 byproduct Substances 0.000 description 9
- -1 carotenoid compounds Chemical class 0.000 description 9
- 235000013339 cereals Nutrition 0.000 description 9
- 230000000408 embryogenic effect Effects 0.000 description 9
- 235000013350 formula milk Nutrition 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 230000009261 transgenic effect Effects 0.000 description 9
- 230000014621 translational initiation Effects 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 241000024188 Andala Species 0.000 description 8
- 108010073771 Soybean Proteins Proteins 0.000 description 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000013599 cloning vector Substances 0.000 description 8
- 235000004626 essential fatty acids Nutrition 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 8
- 238000002703 mutagenesis Methods 0.000 description 8
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 229940001941 soy protein Drugs 0.000 description 8
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 102100027211 Albumin Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 108020005544 Antisense RNA Proteins 0.000 description 7
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 101000912235 Rebecca salina Acyl-lipid (7-3)-desaturase Proteins 0.000 description 7
- 241000172147 Saprolegnia diclina Species 0.000 description 7
- 101000877236 Siganus canaliculatus Acyl-CoA Delta-4 desaturase Proteins 0.000 description 7
- 235000021355 Stearic acid Nutrition 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 230000004186 co-expression Effects 0.000 description 7
- 239000003184 complementary RNA Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000008117 stearic acid Substances 0.000 description 7
- 238000005809 transesterification reaction Methods 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- LWTDZKXXJRRKDG-KXBFYZLASA-N (-)-phaseollin Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-KXBFYZLASA-N 0.000 description 6
- 241000195493 Cryptophyta Species 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- HQPCSDADVLFHHO-LTKCOYKYSA-N all-cis-8,11,14,17-icosatetraenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HQPCSDADVLFHHO-LTKCOYKYSA-N 0.000 description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229960004488 linolenic acid Drugs 0.000 description 6
- 230000002366 lipolytic effect Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 6
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- 101710163504 Phaseolin Proteins 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 230000001851 biosynthetic effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 235000013622 meat product Nutrition 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- 239000006014 omega-3 oil Substances 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- MDTPTXSNPBAUHX-UHFFFAOYSA-M trimethylsulfanium;hydroxide Chemical compound [OH-].C[S+](C)C MDTPTXSNPBAUHX-UHFFFAOYSA-M 0.000 description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 description 5
- BBWMTEYXFFWPIF-CJBMEHDJSA-N (2e,4e,6e)-icosa-2,4,6-trienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C=C\C(O)=O BBWMTEYXFFWPIF-CJBMEHDJSA-N 0.000 description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 244000025670 Eleusine indica Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 102000009114 Fatty acid desaturases Human genes 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 229940063673 spermidine Drugs 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 3
- 101100448444 Caenorhabditis elegans gsp-3 gene Proteins 0.000 description 3
- 101100448445 Caenorhabditis elegans gsp-4 gene Proteins 0.000 description 3
- 239000005496 Chlorsulfuron Substances 0.000 description 3
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 3
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 3
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 3
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 3
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000774835 Heteractis crispa PI-stichotoxin-Hcr2o Proteins 0.000 description 3
- 101000620756 Homo sapiens GTP-binding nuclear protein Ran Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 101710088879 Kunitz trypsin inhibitor 3 Proteins 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 101100393821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GSP2 gene Proteins 0.000 description 3
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008238 biochemical pathway Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 235000013310 margarine Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000012269 metabolic engineering Methods 0.000 description 3
- LWTDZKXXJRRKDG-UHFFFAOYSA-N phaseollin Natural products C1OC2=CC(O)=CC=C2C2C1C1=CC=C3OC(C)(C)C=CC3=C1O2 LWTDZKXXJRRKDG-UHFFFAOYSA-N 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000020991 processed meat Nutrition 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 235000011888 snacks Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- LODRRYMGPWQCTR-UHFFFAOYSA-N 5-fluoro-2,4-dioxo-1h-pyrimidine-6-carboxylic acid;hydrate Chemical compound O.OC(=O)C=1NC(=O)NC(=O)C=1F LODRRYMGPWQCTR-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 241000219194 Arabidopsis Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 2
- 241000195620 Euglena Species 0.000 description 2
- 241000223218 Fusarium Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 101710196768 Seed lectin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000062793 Sorghum vulgare Species 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 241000233675 Thraustochytrium Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000004464 cereal grain Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004332 deodorization Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000009483 enzymatic pathway Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 239000005350 fused silica glass Substances 0.000 description 2
- 229940098330 gamma linoleic acid Drugs 0.000 description 2
- IFYYFLINQYPWGJ-UHFFFAOYSA-N gamma-decalactone Chemical compound CCCCCCC1CCC(=O)O1 IFYYFLINQYPWGJ-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 150000004687 hexahydrates Chemical class 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 108010002685 hygromycin-B kinase Proteins 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- CNVZJPUDSLNTQU-SEYXRHQNSA-N petroselinic acid Chemical compound CCCCCCCCCCC\C=C/CCCCC(O)=O CNVZJPUDSLNTQU-SEYXRHQNSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 235000013324 preserved food Nutrition 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000020989 red meat Nutrition 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 101150116497 sacm1l gene Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 125000002640 tocopherol group Chemical class 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 description 1
- KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 description 1
- LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 1
- 101710161460 3-oxoacyl-[acyl-carrier-protein] synthase Proteins 0.000 description 1
- 102100024088 40S ribosomal protein S7 Human genes 0.000 description 1
- 101150001232 ALS gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010000700 Acetolactate synthase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 101150040074 Aco2 gene Proteins 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 108700021822 Arabidopsis oleosin Proteins 0.000 description 1
- 101000928249 Arabidopsis thaliana Palmitoyl-monogalactosyldiacylglycerol delta-7 desaturase, chloroplastic Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 241000209202 Bromus secalinus Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 101100289888 Caenorhabditis elegans lys-5 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000199913 Crypthecodinium Species 0.000 description 1
- 241000223233 Cutaneotrichosporon cutaneum Species 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- 241001042096 Cyberlindnera tropicalis Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 1
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241000199914 Dinophyceae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000195623 Euglenida Species 0.000 description 1
- 101150070517 FAD6 gene Proteins 0.000 description 1
- 101150061400 Fad4 gene Proteins 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 102000002754 Glycerol-3-Phosphate O-Acyltransferase Human genes 0.000 description 1
- 108010018837 Glycerol-3-Phosphate O-Acyltransferase Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001128156 Homo sapiens Nanos homolog 3 Proteins 0.000 description 1
- 101001124309 Homo sapiens Nitric oxide synthase, endothelial Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910004619 Na2MoO4 Inorganic materials 0.000 description 1
- 102100031893 Nanos homolog 3 Human genes 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- CNVZJPUDSLNTQU-UHFFFAOYSA-N Petroselaidic acid Natural products CCCCCCCCCCCC=CCCCCC(O)=O CNVZJPUDSLNTQU-UHFFFAOYSA-N 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 102000001107 Phosphatidate Phosphatase Human genes 0.000 description 1
- 108010069394 Phosphatidate Phosphatase Proteins 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000011025 Phosphoglycerate Mutase Human genes 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 244000298647 Poinciana pulcherrima Species 0.000 description 1
- 241000201976 Polycarpon Species 0.000 description 1
- 241001505297 Pythium irregulare Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 241001149408 Rhodotorula graminis Species 0.000 description 1
- 241000221523 Rhodotorula toruloides Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000793189 Saccharomyces cerevisiae BY4741 Species 0.000 description 1
- 241000233671 Schizochytrium Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 108010016634 Seed Storage Proteins Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000005601 Trisetum Species 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KYOBSHFOBAOFBF-UHFFFAOYSA-N UMP Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-UHFFFAOYSA-N 0.000 description 1
- 101150050575 URA3 gene Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 241000746966 Zizania Species 0.000 description 1
- 235000002636 Zizania aquatica Nutrition 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010045649 agarase Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000011072 cell harvest Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000014156 coffee whiteners Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical class C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000001214 effect on cellular process Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- IFYYFLINQYPWGJ-VIFPVBQESA-N gamma-Decalactone Natural products CCCCCC[C@H]1CCC(=O)O1 IFYYFLINQYPWGJ-VIFPVBQESA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000012869 germination medium Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000019692 hotdogs Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 101150077696 lip-1 gene Proteins 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 235000010598 long-chain omega-6 fatty acid Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000021032 oily fish Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- KYOBSHFOBAOFBF-ZAKLUEHWSA-N orotidine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O KYOBSHFOBAOFBF-ZAKLUEHWSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- ULBKMFLWMIGVOJ-CFXUUZMDSA-M propicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(CC)OC1=CC=CC=C1 ULBKMFLWMIGVOJ-CFXUUZMDSA-M 0.000 description 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108700012830 rat Lip2 Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108010033405 ribosomal protein S7 Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000005562 seed maturation Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000002316 solid fats Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- AQWHMKSIVLSRNY-UHFFFAOYSA-N trans-Octadec-5-ensaeure Natural products CCCCCCCCCCCCC=CCCCC(O)=O AQWHMKSIVLSRNY-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6431—Linoleic acids [18:2[n-6]]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6434—Docosahexenoic acids [DHA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This invention pertains to a polynucleotide sequence encoding a delta-8 desaturase and the use of this desaturase in making long chain polyunsaturated fatty acids (PUFAs).
- PUFAs long chain polyunsaturated fatty acids
- Lipids/fatty acids are water-insoluble organic biomolecules that can be extracted from cells and tissues by nonpolar solvents such as chloroform, ether or benzene. Lipids have several important biological functions, serving as: (1) structural components of membranes; (2) storage and transport forms of metabolic fuels; (3) a protective coating on the surface of many organisms; and, (4) cell- surface components concerned in cell recognition, species specificity and tissue immunity. More specifically, polyunsaturated fatty acids (PUFAs) are important components of the plasma membrane of the cell, where they may be found in such forms as phospholipids and also can be found in triglycerides.
- PUFAs polyunsaturated fatty acids
- PUFAs also serve as precursors to other molecules of importance in human beings and animals, including the prostacyclins, leukotrienes and prostaglandins.
- There are two main families of PUFAs i.e., the omega-3 fatty acids and the omega-6 fatty acids).
- the human body is capable of producing most of the PUFAs which it requires to function; however, eicosapentaenoic acid (EPA; 20:5, delta-5, 8,11,14,17) and docosahexaenoic acid (DHA; 22:6, delta-4,7,10,13,16,19) cannot be synthesized efficiently by the human body and thus must be supplied through the diet. Since the human body cannot produce adequate quantities of these PUFAs, they are called essential fatty acids. Because of their important roles in human health and nutrition, EPA and DHA are the subject of much interest as discussed herein.
- DHA is a fatty acid of the omega-3 series according to the location of the last double bond in the methyl end. It is synthesized via alternating steps of desatu ration and elongation. Production of DHA is important because of its beneficial effect on human health; for example, increased intake of DHA has been shown to be beneficial or have a positive effect in inflammatory disorders (e.g., rheumatoid arthritis), Type Il diabetes, hypertension, atherosclerosis, depression, myocardial infarction, thrombosis, some cancers and for prevention of the onset of degenerative disorders such as Alzheimer's disease.
- inflammatory disorders e.g., rheumatoid arthritis
- Type Il diabetes hypertension
- atherosclerosis depression
- myocardial infarction thrombosis
- some cancers for prevention of the onset of degenerative disorders such as Alzheimer's disease.
- the major sources of DHA are oils from fish and algae.
- EPA and arachidonic acid are both delta-5 essential fatty acids.
- EPA belongs to the omega-3 series with five double bonds in the acyl chain, is found in marine food, and is abundant in oily fish from the North Atlantic.
- AA belongs to the omega-6 series with four double bonds. The lack of a double bond in the omega-3 position confers on AA different properties than those found in EPA.
- the eicosanoids produced from AA have strong inflammatory and platelet aggregating properties, whereas those derived from EPA have anti ⁇ inflammatory and anti-platelet aggregating properties.
- AA is recognized as the principal ⁇ -6 fatty acid found in the human brain and an important component of breast milk and many infant formulas, based on its role in early neurological and visual development. AA can be obtained from some foods such as meat, fish, and eggs, but the concentration is low.
- GLA Gamma-linolenic acid
- 18:3, delta-6,9,12 is another essential fatty acid found in mammals.
- GLA is the metabolic intermediate for very long chain omega-6 fatty acids and for various active molecules.
- formation of long chain PUFAs is rate-limited by delta-6 desaturation.
- Many physiological and pathological conditions such as aging, stress, diabetes, eczema, and some infections have been shown to depress the delta-6 desaturation step.
- GLA is readily catabolized from the oxidation and rapid cell division associated with certain disorders, e.g., cancer or inflammation.
- omega fatty acids reduce the risk of heart disease, have a positive effect on children's development and on certain mental illnesses, autoimmune diseases and joint complaints.
- PUFAs exert different physiological effects in the body (e.g., most notably, the opposing physiological effects of GLA and AA).
- production of oils using recombinant means is expected to have several advantages over production from natural sources.
- recombinant organisms having preferred characteristics for oil production can be used, since the naturally occurring fatty acid profile of the host can be altered by the introduction of new biosynthetic pathways in the host and/or by the suppression of undesired pathways, thereby resulting in increased levels of production of desired PUFAs (or conjugated forms thereof) and decreased production of undesired PUFAs.
- recombinant organisms can provide PUFAs in particular forms which may have specific uses; or, oil production can be manipulated such that the ratio of omega-3 to omega-6 fatty acids so produced is modified and/or a specific PUFA is produced without significant accumulation of other PUFA downstream or upstream products (e.g., production of oils comprising ARA and lacking GLA).
- delta-6 desaturation pathway The mechanism of PUFA synthesis frequently occurs via the delta-6 desaturation pathway.
- long chain PUFA synthesis in mammals proceeds predominantly by a delta-6 desaturation pathway, in which the first step is the delta-6 desaturation of LA and ALA to yield GLA and stearidonic acid (STA; 18:4, delta-6,9,12,15), respectively.
- STA GLA and stearidonic acid
- Further fatty acid elongation and desaturation steps give rise to AA and EPA.
- delta-6 desaturases, delta-6 elongase components also identified as C18/2 0 elongases
- delta-5 desaturases have been cloned from a variety of organisms including higher plants, algae, mosses, fungi, nematodes and humans.
- WO 98/55625 (published December 19, 1998) describes the production of PUFAs by expression of polyketide-like synthesis genes in plants.
- WO 98/46764 (published October 22, 1998) describes compositions and methods for preparing long chain fatty acids in plants, plant parts and plant cells which utilize nucleic acid sequences and constructs encoding fatty acid desaturases, including delta-5 desaturases, delta-6 desaturases and delta-12 desaturases.
- U.S. 6,075,183 (issued to Knutzon et al. on June 13, 2000) describes methods and compositions for synthesis of long chain PUFAs in plants.
- U.S. 6,459,018 (issued to Knutzon et al. on October 1 , 2002) describes a method for producing STA in plant seed utilizing a construct comprising a DNA sequence encoding a delta-6 desaturase.
- Spychalla et al. (Proc. Natl. Acad. ScL USA, 94:1142-1147 (1997)) describes the isolation and characterization of a cDNA from C. elegans that, when expressed in Arabidopsis, encodes a fatty acid desaturase which can catalyze the introduction of an omega-3 double bond into a range of 18- and 20-carbon fatty acids.
- LA and ALA are first elongated to eicosadienoic acid (EDA; 20:2, delta-11 ,14) and eicosatrienoic acid (EtrA; 20:3, delta-11 ,14, 17), respectively, by a delta-9 elongase.
- EDA eicosadienoic acid
- EtrA eicosatrienoic acid
- delta-8 and delta-5 desaturation of these products yields AA and EPA.
- the delta-8 pathway is present inter alia, in euglenoid species where it is the dominant pathway for formation of 20-carbon PUFAs.
- WO 2000/34439 discloses amino acid and nucleic acid sequences for delta-5 and delta-8 desaturase enzymes. Based on the imormation presented nerein, it is apparent that the delta-8 nucleotide and amino acid sequences of WO 2000/34439 are not correct.
- WO 2004/057001 discloses amino acid and nucleic acid sequences for a delta-8 desaturase enzyme from E. gracilis.
- Biotechnology offers an attractive route for producing long chain PUFAs in a safe, cost efficient manner in microorganisms and plants.
- oil production involves cultivating the microorganism in a suitable culture medium to allow for oil synthesis, followed by separation of the microorganism from the fermentation medium and treatment for recovery of the intracellular oil.
- Attempts have been made to optimize production of fatty acids by fermentive means involving varying such parameters as microorganisms used, media and conditions that permit oil production.
- these efforts have proved largely unsuccessful in improving yield of oil or the ability to control the characteristics of the oil composition produced.
- oleaginous yeasts One class of microorganisms that has not been previously examined as a production platform for PUFAs (prior to work by the Applicants' Assignee), however, are the oleaginous yeasts. These organisms can accumulate oil up to 80% of their dry cell weight. The technology for growing oleaginous yeast with high oil content is well developed (for example, see EP 0 005 277B1; Ratledge, C 1 Prog. Ind.
- Whole yeast cells may also represent a convenient way of encapsulating omega-3 or omega-6 PUFA-enriched oils for use in functional foods and animal feed supplements.
- WO 2004/101757 and WO 2004/101753 (published November 25, 2004) concern the production of PUFAs in oleaginous yeasts and are Applicants' Assignee's copending applications.
- WO 2004/071467 (published August 26, 2004) concerns the production of PUFAs in plants
- WO 2004/071178 (published August 26, 2004) concerns annexin promoters and their use in expression of transgenes in plants; both are Applicants' Assignee's copending applications.
- this invention concerns a recombinant construct comprising SEQ ID NOs:1 or 112 operably linked to at least one regulatory sequence.
- this invention concerns a cell comprising the recombinant construct of the invention.
- this invention concerns a method for transforming cells, plants and yeast with the recombinant construct of the invention.
- this invention concerns seeds obtained from such plants and oil obtained from such seeds.
- this invention concerns a method for making polyunsaturated fatty acids in a cell.
- this invention concerns an oilseed plant comprising a first recombinant DNA construct comprising an isolated polynucleotide encoding a delta-8 desaturase polypeptide, operably linked to at least one regulatory sequence; and at least one additional recombinant DNA construct comprising an isolated polynucleotide, operably linked to at least one regulatory sequence, encoding a polypeptide selected from the group consisting of a delta-4, a delta-5, delta-6, a delta-9, a delta-12, a delta-15, and a delta-17 desaturase, a delta-9 elongase, a
- this invention concerns a method for producing at least one polyunsaturated fatty acid in a soybean cell comprising:
- step (a) transforming a soybean cell with a first recombinant DNA construct comprising an isolated polynucleotide encoding a delta-8 desaturase polypeptide, operably linked to at least one regulatory sequence and at least one additional recombinant DNA construct comprising an isolated polynucleotide, operably linked to at least one regulatory sequence, encoding a polypeptide selected from the group consisting of a delta-4, a delta-5, delta-6, a delta-9, a delta-12, a delta-15, and a delta-17 desaturase, a delta-9 elongase, a C18 to C22 elongase and a C20 to C24 elongase. (b) regenerating a soybean plant from the transformed cell of step (a); and
- this invention concerns an oilseed plant selected from the group consisting of soybean, Brassica species, sunflower, maize, cotton, flax, and safflower.
- this invention concerns oilseed plants wherein the polyunsaturated fatty acid is selected from the group consisting of AA, EDA, EPA, ETA, EtrA, DGLA, DPA, DHA,
- Further embodiments include seeds and oil obtained from the plants transformed with the isolated polynucleotides of the instant invention.
- Additional embodiments concern food, feed and ingredients derived from the processing of the seeds obtained from the plants transformed with the isolated polynucleotides of the instant invention.
- ATCC American Type Culture Collection
- Sequences Listing contains one letter codes for nucleotide sequence characters and the single and three letter codes for amino acids as defined in the IUPAC-IUB standards described in Nucleic Acids Research 13:3021-3030 (1985) and in the Biochemical Journal 219(2):345-373 (1984).
- Figure 1 shows a chromatogram of the lipid profile of an Euglena gracilis cell extract as described in Example 10.
- Figure 2 shows an alignment of the claimed delta-8 desaturase polypeptide sequence from Euglena gracilis (SEQ ID NO:2), a version of a delta-8 desaturase with reduced activity (SEQ ID NO:4) and published non-functional versions of delta- 8 desaturase sequences set forth in gi:5639724 (GenBank Accession No. AAD45877 and SEQ ID NO:6) and in WO 00/34439 or WaIMs et al. (Archives of Biochem. Biophys, 365:307-316 (1999)) (SEQ ID NO:7).
- the method of alignment used corresponds to the "Clustal V method of alignment”.
- Figure 3 provides plasmid maps for the following: (A) yeast expression vector pY89-5 as described in Example 5; and, (B ) soybean expression vector pKR681 as described in Example 6.
- Figure 4 provides plasmid maps for the following: (A) soybean expression vector pKR685 as described in Example 8; and, (B) expression vector pKR274 as described in Example 9.
- Figure 5 provides plasmid maps for the following: (A) yeast expression vector pDMW240 as described in Example 1 ; (B) yeast expression vector pDMW255 as described in Example 1; (C) yeast expression vector pDMW261 as described in Example 1 ; and, (D) vector pKUNFmKF2 as described in Example 14.
- Figure 6 provides plasmid maps for the following: (A) yeast expression vector pDMW277 as described in Example 14; (B) vector pZF5T-PPC as described in Example 14; (C) yeast expression vector pDMW287 as described in Example 14; and, (D) yeast expression vector pDMW287F as described in Example 14.
- Figure 7 provides plasmid maps for the following: (A) vector pZUF17 as described in Example 15; (B) yeast expression vector pDMW237 as described in Example 15; (C) yeast expression vector pKUNT2 as described in Example 16; and, (D) yeast expression vector pDMW297 as described in Example 16.
- Figure 8 provides plasmid maps for the following: (A) soybean expression vector pKR682 as described in Example 17; (B ) soybean expression vector pKR786 as described in Example 18; and, (C) soybean expression vector pKR669 as described in Example 19.
- Figure 9 is a representative PUFA biosynthetic pathway.
- Figure 10 shows a chromatogram of the lipid profile of a soybean embryo extract as described in Example 22.
- SEQ ID NO:1 represents the 1271 bp of the Euglena gracilis sequence containing the ORF (nucleotides 4-1269 (Stop)) of the delta-8 desaturase gene.
- SEQ ID NO:2 is the amino acid sequence encoded by nucleotides 4-1269 of SEQ ID NO:1.
- SEQ ID NO:3 represents the 1271 bp of the Euglena gracilis sequence containing the ORF (nucleotides 4-1269 (Stop)) of the delta-8 desaturase gene containing a guanine for adenine substitution at position 835, as compared to the sequence of SEQ ID NO:1.
- SEQ ID NO:4 is the deduced amino acid sequence encoded by nucleotides 4-1269 of SEQ ID NO:3, which contains an alanine for threonine substitution at position 278, when compared to the polypeptide sequence of SEQ ID NO:2.
- SEQ ID NO:5 represents 1275 bp of the Euglena gracilis sequence set forth in gi:5639724 (GenBank Accession No. AAD45877), containing the ORF
- SEQ ID NO:6 is the deduced amino acid sequence encoded by nucleotides of SEQ ID NO:5 and set forth in gi:5639724.
- SEQ ID NO:7 is the amino acid sequence of a non-functional version of the delta-8 desaturase disclosed in Wallis et al. (Archives of Biochem. Biophys., 365:307-316 (1999) and WO 00/34439).
- SEQ ID NO:8 is the forward primer used for amplification of the delta-8 desaturase from Euglena gracilis in Example 3.
- SEQ ID NO:9 is the reverse primer used for amplification of the delta-8 desaturase from Euglena gracilis in Example 3.
- SEQ ID NO: 10 is the forward primer used for sequencing a delta-8 desaturase clone as described in Example 3.
- SEQ ID NO:11 is the reverse primer used for sequencing a delta-8 desaturase clone as described in Example 3.
- SEQ ID NO:12 is the forward primer used for sequencing a delta-8 desaturase clone as described in Example 3.
- SEQ ID NO: 13 is the reverse primer used for sequencing a delta-8 desaturase clone as described in Example 3.
- SEQ ID NO:14 is the multiple restriction enzyme site sequence introduced in front of the beta-conglycinin promoter as described in Example 6.
- SEQ ID NO: 15 is the forward primer used for amplification of the elongase.
- SEQ ID NO: 16 is the reverse primer used for amplification of the elongase.
- SEQ ID NO: 17 is the multiple restriction enzyme site sequence introduced upstream of the Kti promoter as described in Example 6.
- SEQ ID NO: 18 sets forth the sequence of the soy albumin transcription terminator with restriction enzyme sites as described in Example 6.
- SEQ ID NO:19 is the primer oSalb-12 used for amplification of the albumin transcription terminator.
- SEQ ID NO:20 is primer oSalb-13 used for amplification of the albumin transcription terminator.
- SEQ ID NO:21 is primer GSP1 used for the amplification of the soybean annexin gene.
- SEQ ID NO:22 is primer GSP2 used for the amplification of the soybean annexin gene.
- SEQ ID NO:23 is primer GSP3 used for the amplification of soybean BD30.
- SEQ ID NO:24 is primer GSP4 used for the amplification of soybean BD30.
- SEQ ID NO:25 sets forth the soybean BD30 promoter sequence.
- SEQ ID NO:26 sets forth the soybean Glycinin Gy 1 promoter sequence.
- SEQ ID NO:27 is the forward primer used for amplification of the soybean Glycinin Gy1 promoter sequence.
- SEQ ID NO:28 is the reverse primer used for amplification of the soybean
- SEQ ID NO:29 sets forth the soybean annexin promoter sequence.
- SEQ ID NO:30 is the forward primer used for amplification of the soybean annexin promoter sequence.
- SEQ ID NO:31 is the reverse primer used for amplification of the soybean annexin promoter sequence.
- SEQ ID NO:32 is the forward primer used for amplification of the soybean BD30 promoter sequence.
- SEQ ID NO:33 is the reverse primer used for amplification of the soybean BD30 promoter sequence.
- SEQ ID NO:34 is primer oKTi ⁇ used for amplification of the Kti/ ⁇ /of//Kti 3' cassette.
- SEQ ID NO:35 is primer oKTi6 used for amplification of the KtUNoWKW 3' cassette.
- SEQ ID NO:36 is primer oSBD30-1 used for amplification of the soybean
- SEQ ID NO:37 is primer oSBD30-2 used for amplification of the soybean BD30 3' transcription terminator.
- SEQ ID NO:38 is primer oCGR5-1 used for amplification of the M. alpina delta-6 desaturase.
- SEQ ID NO:39 is primer oCGR5-2 used for amplification of the M. alpina delta-6 desaturase.
- SEQ ID NO:40 is primer oSGIy-1 used for amplification of the glycinin Gy1 promoter.
- SEQ ID NO:41 is primer oSGIy-2 used for amplification of the glycinin Gy1 promoter.
- SEQ ID NO:42 is primer LegPro ⁇ ' used for amplification of the legA2 promoter sequence.
- SEQ ID NO:43 is primer LegPro3' used for amplification of the legA2 promoter sequence.
- SEQ ID NO:44 is primer LegTerm ⁇ ' used for amplification of the leg2A transcription terminator.
- SEQ ID NO:45 is primer LegTerm3' used for amplification of the leg2A transcription terminator.
- SEQ ID NO:46 is primer CGR4forward used for the amplification of the M. alpina desaturase.
- SEQ ID NO:47 is primer CGR4reverse used for the amplification of the M. alpina desaturase.
- SEQ ID NO:48 is the Euglena gracilis sequence, set forth in nucleotides 14- 1275 of SEQ ID NO:5, optimized for codon usage in Yarrowia lipolytics.
- SEQ ID NOs:49-74 correspond to primers D8-1A, ,D8-1A, D8-1 B, D8-2A, D8- 2B, D8-3A, D8-3B, D8-4A, D8-4B, D8-5A, D8-5B, D8-6A, D8-6B, D8-7A, D8-7B, D8-8A, D8-8B, D8-9A, D8-9B, D8-10A, D8-10B, D8-11A, D8-11 B, D8-12A, D8-12B, D8-13A and D8-13B, respectively, used for amplification as described in Example 1.
- SEQ ID Nos:75-82 correspond to primers D8-1 F, D8-3R, D8-4F, D8-6R, D8- 7F, D8-9R, D8-10F and D8-13R, respectively, used for amplification as described in Example 1.
- SEQ ID NO:83 is the 309 bp Nco/Bglll fragment described in Example 1.
- SEQ ID NO:84 is the 321 bp Bglll/Xhol fragment described in Example 1.
- SEQ ID NO:85 is the 264 bp Xhol/Sacl fragment described in Example 1.
- SEQ ID NO:86 is the 369 bp Sac1/Not1 fragment described in Example 1.
- SEQ ID NO:87 is primer ODMW390 used for amplification as described in Example 1.
- SEQ ID NO:88 is primer ODMW391 used for amplification as described in Example 1.
- SEQ ID NO:89 is the chimeric gene described in Example 1.
- SEQ ID NO:90 is the chimeric gene described in Example 1.
- SEQ ID NO:91 is primer ODMW392 used for amplification as described in Example 1.
- SEQ ID NO:92 is primer ODMW393 used for amplification as described in Example 1.
- SEQ ID NO:93 is the synthetic delta-8 desaturase described in Example 1.
- SEQ ID NO:94 is primer ODMW404 used for amplification as described in Example 14.
- SEQ ID NO:95 is the Kpn/Not1 fragment described in Example 14.
- SEQ ID NOs:96-111 correspond to primers YL521 , YL522, YL525, YL526,
- SEQ ID NO:112 is the nucleotide sequence for the synthetic delta-8 desaturase codon-optimized for expression in Yarrowia lipolytics.
- SEQ ID NO:113 is the amino acid sequence encoded by nucleotides 2-1270 of SEQ ID NO:112.
- SEQ ID NO:114 is the DNA sequence (995 bp) of the Yarrowia lipolytica fructose-bisphosphate aldolase promoter containing a Yarrowia intron (FBAIN).
- SEQ ID NO:118 is the nucleotide sequence for the synthetic delta-9 elongase codon-optimized for expression in Yarrowia lipolytica.
- SEQ ID NO:119 is the DNA sequence of the lsochrysis galbana delta-9 elongase (792 bp), while SEQ ID NO:120 is the amino acid sequence of the lsochrysis galbana delta-9 elongase (263 AA).
- SEQ ID NOs: 121 -136 correspond to primers IL3-1A, 1L3-1 B, IL3-2A, IL3-2B, IL3-3A, IL3-3B, IL3-4A, IL3-4B, IL3-5A, IL3-5B, IL3-6A, IL3-6B, IL3-7A, IL3-7B, IL3- 8A and IL3-8B, respectively, used for amplification as described in Example 15.
- SEQ ID NOs:137-140 correspond to primers IL3-1 F, IL3-4R, IL3-5F and IL3- 8R, respectively, used for amplification as described in Example 15.
- SEQ ID NO:141 is the 417 bp Ncol/Pstl fragment described in Example 15.
- SEQ ID NO: 142 is the 377 bp Pstl/Not1 fragment described in Example 15.
- SEQ ID NO:146 is the DNA sequence of the Yarrowia lipolytics delta-12 desaturase (1936 bp), while SEQ ID NO:147 is the amino acid sequence of the Yarrowia lipolytica delta-12 desaturase (419 AA).
- SEQ ID NO: 149 is primer olGsel1-1 used for amplifying a delta-9 elongase as described in Example 17.
- SEQ ID NO:150 is primer olGsel1-2 used for amplifying a delta-9 elongase as described in Example 17.
- SEQ ID NO: 151 is the fragment described in Example 18.
- SEQ ID Nos:115, 116, 117, 143, 144, 145 and 148 are plasmids as identified in Table 1.
- fatty acids refers to long chain aliphatic acids (alkanoic acids) of varying chain lengths, from about C 12 to C 22 (although both longer and shorter chain-length acids are known). The predominant chain lengths are between Ci 6 and C 22 - Additional details concerning the differentiation between "saturated fatty acids” versus "unsaturated fatty acids”, “monounsaturated fatty acids” versus “polyunsaturated fatty acids” (or “PUFAs”), and "omega-6 fatty acids” ( ⁇ -6 or n-6) versus “omega-3 fatty acids” ( ⁇ -3 or ⁇ -3) are provided in WO2004/101757.
- Fatty acids are described herein by a simple notation system of "X:Y", wherein the number before the colon indicates the number of carbon atoms in the fatty acid and the number after the colon is the number of double bonds that are present.
- the number following the fatty acid designation indicates the position of the double bond from the carboxyl end of the fatty acid with the "c" affix for the cis- configuration of the double bond [e.g., palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1 , 9c), petroselinic acid (18:1 , 6c), LA (18:2, 9c, 12c), GLA (18:3, 6c,9c,12c) and ALA (18:3, 9c,12c,15c)].
- 18:1 , 18:2 and 18:3 refer to oleic, LA and linolenic fatty acids. If not specifically written as otherwise, double bonds are assumed to be of the cis configuration. For instance, the double bonds in 18:2 (9,12) would be assumed to be in the cis configuration.
- FIG. 9 A representative pathway is illustrated in Figure 9, providing for the conversion of stearic acid through various intermediates to DHA, which demonstrates how both ⁇ -3 and ⁇ -6 fatty acids may be produced from a common source.
- essential fatty acid refers to a particular PUFA that an organism must ingest in order to survive, being unable to synthesize the particular essential fatty acid de novo.
- mammals can not synthesize the essential fatty acid LA.
- Other essential fatty acids include GLA, DGLA, ARA, EPA and DHA.
- fat refers to a lipid substance that is solid at 25 0 C and usually saturated.
- oil refers to a lipid substance that is liquid at 25 0 C and usually polyunsaturated.
- PUFAs are found in the oils of some algae, oleaginous yeasts and filamentous fungi.
- Microbial oils or “single cell oils” are those oils naturally produced by microorganisms during their lifespan. Such oils can contain long chain PUFAs.
- PUFA biosynthetic pathway refers to a metabolic process that converts oleic acid to LA, EDA, GLA, DGLA, ARA, ALA, STA, ETrA, ETA, EPA, DPA and DHA. This process is well described in the literature (e.g., see
- PUFA biosynthetic pathway enzymes refer to any of the following enzymes (and genes which encode said enzymes) associated with the biosynthesis of a PUFA, including: a delta-4 desaturase, a delta-5 desaturase, a delta-6 desaturase, a delta-12 desaturase, a delta-15 desaturase, a delta-17 desaturase, a delta-9 desaturase, a delta-8 desaturase, a Ci 4/16 elongase, a C16/18 elongase, a C 1 8/20 elongase and/or a C20/22 elongase.
- “Desaturase” is a polypeptide which can desaturate one or more fatty acids to produce a mono- or poly-unsaturated fatty acid or precursor which is of interest.
- delta-8 desaturases that will desaturate a fatty acid between the 8 th and 9 th carbon atom numbered from the carboxyl-terminal end of the molecule and that can, for example, catalyze the conversion of EDA to DGLA and/or ETrA to ETA.
- fatty acid desaturases include, for example: 1.) delta-5 desaturases that catalyze the conversion of DGLA to ARA and/or ETA to EPA; 2.) delta-6 desaturases that catalyze the conversion of LA to GLA and/or ALA to STA; 3.) delta-4 desaturases that catalyze the conversion of DPA to DHA; 4.) delta-12 desaturases that catalyze the conversion of oleic acid to LA; 5.) delta-15 desaturases that catalyze the conversion of LA to ALA and/or GLA to STA; 6.) delta-17 desaturases that catalyze the conversion of ARA to EPA and/or DGLA to ETA; and 7.) delta-9 desaturases that catalyze the conversion of palmitate to palmitoleic acid (16:1) and/or stearate to oleic acid (18:1).
- elongase system refers to a suite of four enzymes that are responsible for elongation of a fatty acid carbon chain to produce a fatty acid that is 2 carbons longer than the fatty acid substrate that the elongase system acts upon. More specifically, the process of elongation occurs in association with fatty acid synthase, whereby CoA is the acyl carrier (Lassner et al., The Plant Cell 8:281-292 (1996)).
- malonyl-CoA is condensed with a long-chain acyl-CoA to yield CO 2 and a ⁇ -ketoacyl-CoA (where the acyl moiety has been elongated by two carbon atoms).
- Subsequent reactions include reduction to ⁇ -hydroxyacyl-CoA, dehydration to an enoyl-CoA and a second reduction to yield the elongated acyl- CoA.
- Examples of reactions catalyzed by elongase systems are the conversion of GLA to DGLA, STA to ETA and EPA to DPA.
- an enzyme catalyzing the first condensation reaction i.e., conversion of malonyl-CoA to ⁇ -ketoacyl-CoA
- elongase an enzyme catalyzing the first condensation reaction
- the substrate selectivity of elongases is somewhat broad but segregated by both chain length and the degree of unsaturation. Accordingly, elongases can have different specificities.
- a C 16718 elongase will utilize a C 16 substrate (e.g., palmitate), a C 18/20 elongase will utilize a C 18 substrate (e.g., GLA, STA) and a C 20722 elongase will utilize a C 20 substrate (e.g., EPA).
- a delta-9 elongase is able to catalyze the conversion of LA and ALA to EDA and ETrA, respectively (see WO 2002/077213).
- elongases have broad specificity and thus a single enzyme may be capable of catalyzing several elongase reactions (e.g., thereby acting as both a C 16718 elongase and a C 18720 elongase).
- delta-9 elongase/ delta-8 desaturase pathway refers to a biosynthetic pathway for production of long chain PUFAs, said pathway minimally comprising a delta-9 elongase and a delta-8 desaturase and thereby enabling biosynthesis of DGLA and/or ETA from LA and ALA, respectively.
- This pathway may be advantageous in some embodiments, as the biosynthesis of GLA and/or STA is excluded.
- polynucleotide polynucleotide sequence
- nucleic acid sequence nucleic acid fragment
- isolated nucleic acid fragment are used interchangeably herein. These terms encompass nucleotide sequences and the like.
- a polynucleotide may be a polymer of RNA or DNA that is single- or double- stranded, that optionally contains synthetic, non-natural or altered nucleotide bases.
- a polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof.
- Nucleotides are referred to by a single letter designation as follows: "A” for adenylate or deoxyadenylate (for RNA or DNA, respectively), “C” for cytidylate or deoxycytidylate, “G” for guanylate or deoxyguanylate, “U” for uridylate, “T” for deoxythymidylate, “R” for purines (A or G), “Y” for pyrimidines (C or T), "K” for G or T, “H” for A or C or T, T for inosine, and “N” for any nucleotide.
- fragment that is functionally equivalent and “functionally equivalent subfragment” are used interchangeably herein. These terms refer to a portion or subsequence of an isolated nucleic acid fragment in which the ability to alter gene expression or produce a certain phenotype is retained whether or not the fragment or subfragment encodes an active enzyme.
- the fragment or subfragment can be used in the design of chimeric genes to produce the desired phenotype in a transformed plant. Chimeric genes can be designed for use in suppression by linking a nucleic acid fragment or subfragment thereof, whether or not it encodes an active enzyme, in the sense or antisense orientation relative to a plant promoter sequence.
- nucleic acid fragments wherein changes in one or more nucleotide bases do not affect the ability of the nucleic acid fragment to mediate gene expression or produce a certain phenotype.
- modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially alter the functional properties of the resulting nucleic acid fragment relative to the initial, unmodified fragment. It is therefore understood, as those skilled in the art will appreciate, that the invention encompasses more than the specific exemplary sequences.
- substantially similar nucleic acid sequences encompassed by this invention are also defined by their ability to hybridize (under moderately stringent conditions, e.g., 0.5X SSC, 0.1% SDS, 60 0 C) with the sequences exemplified herein, or to any portion of the nucleotide sequences disclosed herein and which are functionally equivalent to any of the nucleic acid sequences disclosed herein.
- Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions.
- One set of preferred conditions involves a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45 0 C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50 0 C for 30 min.
- a more preferred set of stringent conditions involves the use of higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60 0 C.
- Another preferred set of highly stringent conditions involves the use of two final washes in 0.1 X SSC, 0.1 % SDS at 65 0 C.
- Gene refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence.
- “Native gene” refers to a gene as found in nature with its own regulatory sequences.
- “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature.
- a “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes.
- a “transgene” is a gene that has been introduced into the genome by a transformation procedure.
- a “codon-optimized gene” is a gene having its frequency of codon usage designed to mimic the frequency of preferred codon usage of the host cell.
- an "allele” is one of several alternative forms of a gene occupying a given locus on a chromosome. When all the alleles present at a given locus on a chromosome are the same that plant is homozygous at that locus. If the alleles present at a given locus on a chromosome differ that plant is heterozygous at that locus.
- Coding sequence refers to a DNA sequence that codes for a specific amino acid sequence.
- Regulatory sequences refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include, but are not limited to: promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites and stem-loop structures.
- Promoter refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA.
- the promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers.
- an “enhancer” is a DNA sequence that can stimulate promoter activity, and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments.
- promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of some variation may have identical promoter activity. Promoters that cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro, J. K., and Goldberg, R. B. Biochemistry of Plants 15:1-82 (1989).
- Translation leader sequence refers to a polynucleotide sequence located between the promoter sequence of a gene and the coding sequence.
- the translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence.
- the translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner, R. and Foster, G. D., MoI. Biotechnol. 3:225-236 (1995)).
- 3' non-coding sequences refer to DNA sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression.
- the polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor.
- the use of different 3' non-coding sequences is exemplified by Ingelbrecht, I. L., et al. Plant Cell 1 :671-680 (1989).
- RNA transcript refers to the product resulting from RNA polymerase- catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript. A RNA transcript is referred to as the mature RNA when it is a RNA sequence derived from post-transcriptional processing of the primary transcript.
- Messenger KNA or " (DKiNlA” refers to tne KNA that is without introns and that can be translated into protein by the cell.
- cDNA refers to a DNA that is complementary to, and synthesized from, a mRNA template using the enzyme reverse transcriptase.
- RNA transcript that includes the mRNA and can be translated into protein within a cell or in vitro.
- Antisense RNA refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA, and that blocks the expression of a target gene (U.S. 5,107,065). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence.
- RNA refers to antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.
- complement and “reverse complement” are used interchangeably herein with respect to mRNA transcripts, and are meant to define the antisense RNA of the message.
- operably linked refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is regulated by the other.
- a promoter is operably linked with a coding sequence when it is capable of regulating the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).
- Coding sequences can be operably linked to regulatory sequences in a sense or antisense orientation.
- the complementary RNA regions of the invention can be operably linked, either directly or indirectly, 5' to the target mRNA, or 3' to the target mRNA, or within the target mRNA, or a first complementary region is 5' and its complement is 3' to the target mRNA.
- PCR Polymerase Chain Reaction
- PCR Polymerase Chain Reaction
- cycles Perkin Elmer Cetus Instruments, Norwalk, CT.
- the double- stranded DNA is heat denatured, the two primers complementary to the 3' boundaries of the target segment are annealed at low temperature and then extended at an intermediate temperature.
- One set of these three consecutive steps is referred to as a "cycle”.
- the term "recombinant” refers to an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques.
- Plasmid refers to an extra chromosomal element often carrying genes that are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA fragments.
- Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell.
- Transformation cassette refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitates transformation of a particular host cell.
- Expression cassette refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.
- a recombinant construct comprises an artificial combination of nucleic acid fragments, e.g., regulatory and coding sequences that are not found together in nature.
- a chimeric construct may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature.
- Such a construct may be used by itself or may be used in conjunction with a vector. If a vector is used, then the choice of vector is dependent upon the method that will be used to transform host cells as is well known to those skilled in the art.
- a plasmid vector can be used.
- the skilled artisan is well aware of the genetic elements that must be present on the vector in order to successfully transform, select and propagate host cells comprising any of the isolated nucleic acid fragments of the invention.
- the skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al., EMBO J. 4:2411-2418 (1985); De Almeida et al., MoI. Gen. Genetics 218:78-86 (1989)), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern.
- Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, immunoblotting analysis of protein expression, or phenotypic analysis, among others.
- expression refers to the production of a functional end-product (e.g., a mRNA or a protein [either precursor or mature]).
- expression cassette refers to a discrete nucleic acid fragment into which a nucleic acid sequence or fragment can be moved.
- “Mature” protein refers to a post-translationally processed polypeptide (i.e., one from which any pre- or propeptides present in the primary translation product have been removed).
- Precursor protein refers to the primary product of translation of mRNA (i.e., with pre- and propeptides still present). Pre- and propeptides may be but are not limited to intracellular localization signals.
- Stable transformation refers to the transfer of a nucleic acid fragment into a genome of a host organism, including both nuclear and organellar genomes, resulting in genetically stable inheritance.
- transient transformation refers to the transfer of a nucleic acid fragment into the nucleus, or DNA-containing organelle, of a host organism resulting in gene expression without integration or stable inheritance.
- Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms.
- Antisense inhibition refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein.
- Co-suppression refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. 5,231 ,020). Co-suppression constructs in plants previously have been designed by focusing on overexpression of a nucleic acid sequence having homology to an endogenous mRNA, in the sense orientation, which results in the reduction of all RNA having homology to the overexpressed sequence (Vaucheret et al., Plant J. 16:651-659 (1998); Gura, Nature 404:804-808 (2000)).
- oleaginous refers to those organisms that tend to store their energy source in the form of lipid (Weete, In: Fungal Lipid Biochemistry, 2 nd Ed., Plenum, 1980). Generally, the cellular oil content of these microorganisms follows a sigmoid curve, wherein the concentration of lipid increases until it reaches a maximum at the late logarithmic or early stationary growth phase and then gradually decreases during the late stationary and death phases (Yongmanitchai and Ward, Appl. Environ. Microbiol. 57:419-25 (1991)).
- oleaginous yeast refers to those microorganisms classified as yeasts that make oil. It is not uncommon for oleaginous microorganisms to accumulate in excess of about 25% of their dry cell weight as oil. Examples of oleaginous yeast include, but are no means limited to, the following genera: Yarrowia, Candida, Rhodotorula, Rhodosporidium, Cryptococcus, Trichosporon and Lipomyces.
- the "Clustal V method of alignment” corresponds to the alignment method labeled Clustal V (described by Higgins and Sharp, CABIOS. 5:151-153 (1989)) and found in the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wl).
- the present invention concerns an isolated polynucleotide comprising: (a) a nucleotide sequence encoding a polypeptide having delta-8 desaturase activity, wherein the polypeptide has an amino acid sequnce consisting essentially of SEQ ID NOs:2 or 113; or,
- This delta-8 desaturase may be used alone or in combination with other desaturase and elongase components to produce various omega-6 and omega-3 PUFAs, including e.g., DGLA, ETA 1 ARA, EPA, DPA and/or DHA ( Figure 9).
- this invention concerns a recombinant construct comprising the polynucleotide of the invention operably linked to at least one regulatory sequence.
- a promoter is a DNA sequence that directs cellular machinery of a plant to produce RNA from the contiguous coding sequence downstream (3 1 ) of the promoter.
- the promoter region influences the rate, developmental stage, and cell type in which the RNA transcript of the gene is made.
- the RNA transcript is processed to produce mRNA which serves as a template for translation of the RNA sequence into the amino acid sequence of the encoded polypeptide.
- the 5' non-translated leader sequence is a region of the mRNA upstream of the protein coding region that may play a role in initiation and translation of the mRNA.
- the 3 1 transcription termination/polyadenylation signal is a non-translated region downstream of the protein coding region that functions in the plant cell to cause termination of the RNA transcript and the addition of polyadenylate nucleotides to the 3 1 end of the RNA.
- the origin of the promoter chosen to drive expression of the coding sequence is not important as long as it has sufficient transcriptional activity to accomplish the invention by expressing translatable mRNA for the desired nucleic acid fragments in the desired host tissue at the right time.
- Either heterologous or non-heterologous (i.e., endogenous) promoters can be used to practice the invention.
- suitable promoters include, but are not limited to: the alpha prime subunit of beta conglycinin promoter, Kunitz trypsin inhibitor 3 promoter, annexin promoter, GIyI promoter, beta subunit of beta conglycinin promoter, P34/Gly Bd m 3OK promoter, albumin promoter, Leg A1 promoter and Leg A2 promoter.
- the annexin, or P34, promoter is described in WO 2004/071178 (published August 26, 2004).
- the level of activity of the annexin promoter is comparable to that of many known strong promoters, such as: (1) the CaMV 35S promoter (Atanassova et al., Plant MoI. Biol. 37:275-285 (1998); Battraw and Hall, Plant MoI. Biol. 15:527-538 (1990); Holtorf et al., Plant MoI. Biol. 29:637-646 (1995); Jefferson et al., EMBO J. 6:3901-3907 (1987); Wilmink et al., Plant MoI. Biol.
- annexin promoter is its expression profile in developing seeds.
- the annexin promoter is most active in developing seeds at early stages (before 10 days after pollination) and is largely quiescent in later stages.
- the expression profile of the annexin promoter is different from that of many seed-specific promoters, e.g., seed storage protein promoters, which often provide highest activity in later stages of development (Chen et al., Dev. Genet.
- the annexin promoter has a more conventional expression profile but remains distinct from other known seed specific promoters. Thus, the annexin promoter will be a very attractive candidate when overexpression, or suppression, of a gene in embryos is desired at an early developing stage. For example, it may be desirable to overexpress a gene regulating early embryo development or a gene involved in the metabolism prior to seed maturation.
- the promoter is then operably linked in a sense orientation using conventional means well known to those skilled in the art.
- the recombinant construct may then be introduced into a plant cell of choice by methods well known to those of ordinary skill in the art (e.g., transfection, transformation and electroporation).
- Oilseed plant cells are the preferred plant cells.
- the transformed plant cell is then cultured and regenerated under suitable conditions permitting expression of the long chain PUFA which is then optionally recovered and purified.
- the recombinant constructs of the invention may be introduced into one plant cell; or, alternatively, each construct may be introduced into separate plant cells.
- Expression in a plant cell may be accomplished in a transient or stable fashion as is described above.
- the desired long chain PUFAs can be expressed in seed. Also within the scope of this invention are seeds or plant parts obtained from such transformed plants.
- Plant parts include differentiated and undifferentiated tissues including, but not limited to: roots, stems, shoots, leaves, pollen, seeds, tumor tissue and various forms of cells and culture (e.g., single cells, protoplasts, embryos and callus tissue).
- the plant tissue may be in plant or in a plant organ, tissue or cell culture.
- plant organ refers to plant tissue or group of tissues that constitute a morphologically and functionally distinct part of a plant.
- the term “genome” refers to the following: 1. The entire complement of genetic material (genes and non- coding sequences) is present in each cell of an organism, or virus or organelle. 2. A complete set of chromosomes inherited as a (haploid) unit from one parent.
- this invention also concerns a method for transforming a cell, comprising transforming a cell with the recombinant construct of the invention and selecting those cells transformed with the recombinant construct of Claim 4.
- Also of interest is a method for producing a transformed plant comprising transforming a plant cell with the polynucleotide of the instant invention and regenerating a plant from the transformed plant cell.
- the particular method of regeneration will depend on the starting plant tissue and the particular plant species to be regenerated.
- the regeneration, development and cultivation of plants from single plant protoplast transformants or from various transformed explants is well known in the art (Weissbach and Weissbach, In: Methods for Plant Molecular Biology, (Eds.), Academic: San Diego, CA (1988)).
- This regeneration and growth process typically includes the steps of selection of transformed cells and culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage. Transgenic embryos and seeds are similarly regenerated. The resulting transgenic rooted shoots are thereafter planted in an appropriate plant growth medium such as soil.
- the regenerated plants are self-pollinated to provide homozygous transgenic plants. Otherwise, pollen obtained from the regenerated plants is crossed to seed-grown plants of agronomically important lines. Conversely, pollen from plants of these important lines is used to pollinate regenerated plants.
- a transgenic plant of the present invention containing a desired polypeptide is cultivated using methods well known to one skilled in the art.
- oilseed plants include, but are not limited to, soybean, Brassica species, sunflower, maize, cotton, flax, safflower.
- polyunsaturated fatty acids having at least twenty carbon atoms and five or more carbon-carbon double bonds include, but are not limited to, omega- 3 fatty acids such as EPA, DPA and DHA. Seeds obtained from such plants are also within the scope of this invention as well as oil obtained from such seeds.
- this invention concerns an oilseed plant comprising: a) a first recombinant DNA construct comprising an isolated polynucleotide encoding a delta-8 desaturase polypeptide, operably linked to at least one regulatory sequence; and b) at least one additional recombinant DNA construct comprising an isolated polynucleotide, operably linked to at least one regulatory sequence, encoding a polypeptide selected from the group consisting of a delta-4, a delta-5, delta-6, a delta-9, a delta-12, a delta-15, and a delta-17 desaturase, a delta-9 elongase, a C18 to C22 elongase and a C20 to C24 elongase.
- Such desaturases are discussed in U.S. Patent Nos. 6,075,183, 5,968,809,
- cassettes used depends in part on the PUFA profile and/or desaturase profile of the oilseed plant cells to be transformed and the LC-PUFA which is to be expressed.
- this invention concerns a method for making long chain polyunsaturated fatty acids in a plant cell comprising:
- this invention concerns a method for producing at least one polyunsaturated fatty acid in a soybean cell comprising: '
- step (b) regenerating a soybean plant from the transformed cell of step (a);
- step (c) selecting those seeds obtained from the plants of step (b) having an altered level of polyunsaturated fatty acids when compared to the level in seeds obtained from a nontransformed soybean plant.
- soybean oil is produced using a series of steps involving the extraction and purification of an edible oil product from the oil-bearing seed. Soybean oils and soybean byproducts are produced using the generalized steps shown in the Table below.
- soybean oil is produced using a series of steps involving the extraction and purification of an edible oil product from the oil bearing seed.
- Soybean oils and soybean byproducts are produced using the generalized steps shown in the diagram below.
- soybean seeds are cleaned, tempered, dehulled and flaked, thereby increasing the efficiency of oil extraction.
- Oil extraction is usually accomplished by solvent (e.g., hexane) extraction but can also be achieved by a combination of physical pressure and/or solvent extraction.
- the resulting oil is called crude oil.
- the crude oil may be degummed by hydrating phospholipids and other polar and neutral lipid complexes that facilitate their separation from the nonhydrating, triglyceride fraction (soybean oil).
- the resulting lecithin gums may be further processed to make commercially important lecithin products used in a variety of food and industrial products as emulsification and release (i.e., antisticking) agents.
- Degummed oil may be further refined for the removal of impurities (primarily free fatty acids, pigments and residual gums). Refining is accomplished by the addition of a caustic agent that reacts with free fatty acid to form soap and hydrates phosphatides and proteins in the crude oil. Water is used to wash out traces of soap formed during refining. The soapstock byproduct may be used directly in animal feeds or acidulated to recover the free fatty acids. Color is removed through adsorption with a bleaching earth that removes most of the chlorophyll and carotenoid compounds. The refined oil can be hydrogenated, thereby resulting in fats with various melting properties and textures. Winterization (fractionation) may be used to remove stearine from the hydrogenated oil through crystallization under carefully controlled cooling conditions. Deodorization
- Soybean oil is liquid at room temperature because it is relatively low in saturated fatty acids when compared with oils such as coconut, palm, palm kernel and cocoa butter.
- oils such as coconut, palm, palm kernel and cocoa butter.
- Many processed fats including spreads, confectionary fats, hard butters, margarines, baking shortenings, etc.) require varying degrees of solidity at room temperature and can only be produced from soybean oil through alteration of its physical properties. This is most commonly achieved through catalytic hydrogenation.
- Hydrogenation is a chemical reaction in which hydrogen is added to the unsaturated fatty acid double bonds with the aid of a catalyst such as nickel.
- High oleic soybean oil contains unsaturated oleic, LA and linolenic fatty acids and each of these can be hydrogenated. Hydrogenation has two primary effects. First, the oxidative stability of the oil is increased as a result of the reduction of the unsaturated fatty acid content. Second, the physical properties of the oil are changed because the fatty acid modifications increase the melting point resulting in a semi-liquid or solid fat at room temperature.
- Examples of food products or food analogs into which altered seed oils or altered seeds of the invention may be incorporated include a meat product such as a processed meat product, a cereal food product, a snack food product, a baked goods product, a fried food product, a health food product, an infant formula, a beverage, a nutritional supplement, a dairy product, a pet food product, animal feed or an aquaculture food product.
- a meat product such as a processed meat product, a cereal food product, a snack food product, a baked goods product, a fried food product, a health food product, an infant formula, a beverage, a nutritional supplement, a dairy product, a pet food product, animal feed or an aquaculture food product.
- Food analogs can be made use processes well known to those skilled in the art.
- U.S. Patent Nos. 6,355,296 B1 and 6,187,367 B1 describe emulsified meat analogs and emulsified meat extenders.
- U.S. Patent No. 4,284,656 to Hwa describes a soy protein curd useful for food analogs.
- U.S. Patent No. 3,988,485 to Hibbert et al. describes a meat-like protein food formed from spun vegetable protein fibers.
- U.S. Patent No. 3,950,564 to Puski et al. describes a process of making a soy based meat substitute and
- U.S. Patent No. 3,925,566 to Reinhart et al. describes a simulated meat product.
- soy protein that has been processed to impart a structure, chunk or fiber for use as a food ingredient is called "textured soy protein" (TSP). TSPs are frequently made to resemble meat, seafood, or poultry in structure and appearance when hydrated.
- TSP textured soy protein
- Meat analogs made from soybeans contain soy protein or tofu and other ingredients mixed together to simulate various kinds of meats. These meat alternatives are sold as frozen, canned or dried foods. Usually, they can be used the same way as the foods they replace. Meat alternatives made from soybeans are excellent sources of protein, iron and B vitamins. Examples of meat analogs include, but are not limited to, ham analogs, sausage analogs, bacon analogs, and the like.
- Food analogs can be classified as imitiation or substitutes depending on their functional and compositional characteristics. For example, an imitation cheese need only resemble the cheese it is designed to replace. However, a product can generally be called a substitute cheese only if it is nutritionally equivalent to the cheese it is replacing and meets the minimum compositional requirements for that cheese. Thus, substitute cheese will often have higher protein levels than imitation cheeses and be fortified with vitamins and minerals.
- Milk analogs or nondairy food products include, but are not limited to, imitation milk, nondairy frozen desserts such as those made from soybeans and/or soy protein products. Meat products encompass a broad variety of products. In the United States "meat” includes "red meats" produced from cattle, hogs and sheep.
- poultry items which include chickens, turkeys, geese, guineas, ducks and the fish and shellfish.
- meat products fresh, cured and fried, and cured and cooked.
- Sausages and hot dogs are examples of processed meat products.
- meat products as used herein includes, but is not limited to, processed meat products.
- a cereal food product is a food product derived from the processing of a cereal grain.
- a cereal grain includes any plant from the grass family that yields an edible grain (seed). The most popular grains are barley, corn, millet, oats, quinoa, rice, rye, sorghum, triticale, wheat and wild rice. Examples of a cereal food product include, but are not limited to, whole grain, crushed grain, grits, flour, bran, germ, breakfast cereals, extruded foods, pastas, and the like.
- a baked goods product comprises any of the cereal food products mentioned above and has been baked or processed in a manner comparable to baking, i.e., to dry or harden by subjecting to heat.
- Examples of a baked good product include, but are not limited to bread, cakes, doughnuts, bread crumbs, baked snacks, mini- biscuits, mini-crackers, mini-cookies, and mini-pretzels.
- oils of the invention can be used as an ingredient.
- a snack food product comprises any of the above or below described food products.
- a fried food product comprises any of the above or below described food products that has been fried.
- a health food product is any food product that imparts a health benefit. Many oilseed-derived food products may be considered as health foods.
- the beverage can be in a liquid or in a dry powdered form.
- Non-carbonated drinks there can be mentioned non-carbonated drinks; fruit juices, fresh, frozen, canned or concentrate; flavored or plain milk drinks, etc.
- Infant and infant nutritional formulas are well known in the art and commercially available (e.g., Similac®, Ensure®, Jevity®, and Alimentum® from Ross Products Division, Abbott Laboratories). Infant formulas are liquids or reconstituted powders fed to infants and young children. They serve as substitutes for human milk. Infant formulas have a special role to play in the diets of infants because they are often the only source of nutrients for infants. Although breast-feeding is still the best nourishment for infants, infant formula is a close enough second that babies not only survive but thrive. Infant formula is becoming more and more increasingly close to breast milk.
- a dairy product is a product derived from milk.
- a milk analog or nondairy product is derived from a source other than milk, for example, soymilk as was discussed above.
- These products include, but are not limited to, whole milk, skim milk, fermented milk products such as yogurt or sour milk, cream, butter, condensed milk, dehydrated milk, coffee whitener, coffee creamer, ice cream, cheese, etc.
- a pet food product is a product intended to be fed to a pet such as a dog, cat, bird, reptile, fish, rodent and the like.
- These products can include the cereal and health food products above, as well as meat and meat byproducts, soy protein products, grass and hay products, including but not limited to alfalfa, timothy, oat or brome grass, vegetables and the like.
- Animal feed is a product intended to be fed to animals such as turkeys, chickens, cattle and swine and the like.
- these products can include cereal and health food products, soy protein products, meat and meat byproducts, and grass and hay products as listed above.
- Aqualculture feed is a product intended to be used in aquafarming which concerns the propagation, cultivation or farming of aquatic organisms, animals and/or plants in fresh or marine waters.
- Palmitate (16:0) in oleaginous microorganisms is described in WO 2004/101757.
- This fatty acid is the precursor of longer-chain saturated and unsaturated fatty acid derivates, which are formed through the action of elongases and desaturases.
- palmitate is converted to its unsaturated derivative [palmitoleic acid (16:1)] by the action of a delta-9 desaturase; similarly, palmitate is elongated to form stearic acid (18:0), which can be converted to its unsaturated derivative by a delta-9 desaturase to thereby yield oleic (18:1) acid.
- Triacy Ig lycerols (the primary storage unit for fatty acids) are formed by the esterification of two molecules of acyl-CoA to glycerol-3-phosphate to yield 1 ,2- diacylglycerol phosphate (commonly identified as phosphatidic acid). The phosphate is then removed, by phosphatidic acid phosphatase, to yield 1 ,2- diacylglycerol. Triacy Ig lycerol is formed upon the addition of a third fatty acid by the action of a diacylglycerol-acyl transferase.
- the particular functionalities required to be introduced into a microbial host organism for production of a particular PUFA final product will depend on the host cell (and its native PUFA profile and/or desaturase/elongase profile), the availability of substrate and the desired end product(s).
- LA, GLA, EDA, DGLA, ARA, ALA, STA, ETrA, ETA, EPA, DPA and DHA may all be produced in oleaginous yeasts, by introducing various combinations of the following PUFA enzyme functionalities: a delta-4 desaturase, a delta-5 desaturase, a delta-6 desaturase, a delta-8 desaturase, a delta-12 desaturase, a delta-15 desaturase, a delta-17 desaturase, a delta-9 desaturase, a C14/16 elongase, a Ci 6 /i8 elongase, a C18/20 elongase and/or a C20/22 elongase.
- PUFA enzyme functionalities a delta-4 desaturase, a delta-5 desaturase, a delta-6 desaturase, a delta-8 desaturase, a delta-12 desaturase, a delta-15 desaturase, a
- sequences may be derived from any source, e.g., isolated from a natural source (from bacteria, algae, fungi, plants, animals, etc.), produced via a semi-synthetic route or synthesized de novo.
- manipulation of genes endogenous to the host is preferred; for other purposes, it is necessary to introduce heterologous genes.
- the particular source of the desaturase and elongase genes introduced into the host is not critical to the invention, considerations for choosing a specific polypeptide having desaturase or elongase activity include: 1.) the substrate specificity of the polypeptide; 2.) whether the polypeptide or a component thereof is a rate-limiting enzyme; 3.) whether the desaturase or elongase is essential for synthesis of a desired PUFA; and/or 4.) co-factors required by the polypeptide.
- the expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell. For example, the polypeptide may have to compete for substrate with other enzymes in the host cell.
- Analyses of the K ⁇ and specific activity of the polypeptide are therefore considered in determining the suitability of a given polypeptide for modifying PUFA production in a given host cell.
- the polypeptide used in a particular host cell is one that can function under the biochemical conditions present in the intended host cell but otherwise can be any polypeptide having desaturase or elongase activity capable of modifying the desired PUFA.
- the host organism in which it is desirable to produce PUFAs will possess endogenous genes encoding some PUFA biosynthetic pathway enzymes.
- oleaginous yeast can typically produce 18:2 fatty acids (and some have the additional capability of synthesizing 18:3 fatty acids); thus, oleaginous yeast typically possess native delta-12 desaturase activity and may also have delta-15 desaturases.
- expression of the native desaturase enzyme is preferred over a heterologous (or "foreign") enzyme since: 1.) the native enzyme is optimized for interaction with other enzymes and proteins within the cell; and 2.) heterologous genes are unlikely to share the same codon preference in the host organism.
- omega-3 and/or omega-6 PUFA production may be optimized by selection of a particular desaturase or elongase whose level of expression in a heterologous host is preferred relative to the expression of an alternate desaturase or elongase in the host organism of interest.
- a variety of genetic engineering techniques are available to optimize expression of a particular enzyme. Two such techniques include codon optimization and gene mutation, as described below. Genes produced by e.g., either of these two methods, having desaturase and/or elongase activity(s) would be useful in the invention herein for synthesis of omega-3 and/or omega-6 PUFAs.
- Codon Optimization As will be appreciated by one skilled in the art, it is frequently useful to modify a portion of the codons encoding a particular polypeptide that is to be expressed in a foreign host, such that the modified polypeptide uses codons that are preferred by the alternate host. Use of host-preferred codons can substantially enhance the expression of the foreign gene encoding the polypeptide. In general, host-preferred codons can be determined within a particular host species of interest by examining codon usage in proteins (preferably those expressed in the largest amount) and determining which codons are used with highest frequency.
- the coding sequence for a polypeptide of interest having desaturase or elongase activity can be synthesized in whole or in part using the codons preferred in the host species. All (or portions) of the DNA also can be synthesized to remove any destabilizing sequences or regions of secondary structure that would be present in the transcribed mRNA. All (or portions) of the DNA also can be synthesized to alter the base composition to one more preferable in the desired host cell.
- the nucleic acid sequence of the native gene e.g., the Euglena gracilis delta-8 desaturase defined herein as Eg5
- Eg5 the Euglena gracilis delta-8 desaturase defined herein as Eg5
- This wildtype desaturase has 421 amino acids (SEQ ID NO:2); in the codon-optimized gene created herein (SEQ ID NO:112), 207 bp of the 1263 bp coding region (corresponding to 192 codons) were codon-optimized and the translation initiation site was modified.
- Gene Mutation Methods for synthesizing sequences and bringing sequences together are well established in the literature. For example, in vitro mutagenesis and selection, site-directed mutagenesis, error prone PCR (Melnikov et al., Nucleic Acids Research, 27(4): 1056-1062 (February 15, 1999)), "gene shuffling" or other means can be employed to obtain mutations of naturally occurring desaturase or elongase genes (wherein such mutations may include deletions, insertions and point mutations, or combinations thereof).
- a polypeptide having desaturase or elongase activity in vivo with more desirable physical and kinetic parameters for function in the host cell such as a longer half-life or a higher rate of production of a desired PUFA.
- the regions of a polypeptide of interest i.e., a desaturase or an elongase
- the regions of a polypeptide of interest can be determined through routine mutagenesis, expression of the resulting mutant polypeptides and determination of their activities. An overview of these techniques are described in WO 2004/101757. All such mutant proteins and nucleotide sequences encoding them that are derived from the codon-optimized gene described herein are within the scope of the present invention.
- Microbial Production of Omega-3 And/Or Omega-6 Fatty Acids has several advantages. For example: 1.) many microbes are known with greatly simplified oil compositions compared with those of higher organisms, making purification of desired components easier; 2.) microbial production is not subject to fluctuations caused by external variables, such as weather and food supply; 3.) microbially produced oil is substantially free of contamination by environmental pollutants; 4.) microbes can provide PUFAs in particular forms which may have specific uses; and 5.) microbial oil production can be manipulated by controlling culture conditions, notably by providing particular substrates for microbially expressed enzymes, or by addition of compounds/genetic engineering to suppress undesired biochemical pathways.
- omega-3 and/or omega-6 fatty acids from recombinant microbes provides the ability to alter the naturally occurring microbial fatty acid profile by providing new biosynthetic pathways in the host or by suppressing undesired pathways, thereby increasing levels of desired PUFAs, or conjugated forms thereof, and decreasing levels of undesired PUFAs.
- omega-3 to omega-6 fatty acids so produced, produce either omega-3 or omega-6 fatty acids exclusively while eliminating production of the alternate omega fatty acid, or engineer production of a specific PUFA without significant accumulation of other PUFA downstream or upstream products (e.g., enable biosynthesis of ARA, EPA and/or DHA via the delta-9 elongase/delta-8 desaturase pathway, thereby avoiding synthesis of GLA and/or STA).
- genes and gene products described herein may be produced in heterologous microbial host cells, particularly in the cells of oleaginous yeasts (e.g., Yarrowia lipolytica). Expression in recombinant microbial hosts may be useful for the production of various PUFA pathway intermediates, or for the modulation of PUFA pathways already existing in the host for the synthesis of new products heretofore not possible using the host.
- Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct chimeric genes for production of any of the gene products of the preferred desaturase and/or elongase sequences. These chimeric genes could then be introduced into appropriate microorganisms via transformation to provide high-level expression of the encoded enzymes. Accordingly, it is expected that introduction of chimeric genes encoding a PUFA biosynthetic pathway, under the control of the appropriate promoters will result in increased production of omega-3 and/or omega-6 fatty acids.
- an expression cassette may be constructed comprising genes encoding one or more of the following enzymatic activities: a delta-4 desaturase, a delta-5 desaturase, a delta-6 desaturase, a delta-8 desaturase, a delta-12 desaturase, a delta-15 desaturase, a delta-17 desaturase, a delta-9 desaturase, a Cu / i ⁇ elongase, a C 16/ is elongase, a C-18/ 2 0 elongase and/or a C20/22 elongase.
- the present invention encompasses a method of producing PUFAs comprising exposing a fatty acid substrate to the PUFA enzyme(s) described herein, such that the substrate is converted to the desired fatty acid product.
- each PUFA gene and corresponding enzyme product described herein e.g., a wildtype, codon-optimized, synthetic and/or mutant enzyme having appropriate desaturase or elongase activity
- direct production of PUFAs occurs wherein the fatty acid substrate is converted directly into the desired fatty acid product without any intermediate steps or pathway intermediates.
- the present invention is drawn to a method of producing either DGLA or ETA, respectively, comprising: a) providing an oleaginous yeast comprising: (i) a gene encoding a delta- 8 desaturase polypeptide as set forth in SEQ ID NO: 112; and
- step (ii) a source of desaturase substrate consisting of either EDA or ETrA, respectively; and, b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding a delta-8 desaturase polypeptide is expressed and EDA is converted to DGLA or ETrA is converted to ETA, respectively; and, c) optionally recovering the DGLA or ETA, respectively, of step (b).
- multiple genes encoding the PUFA biosynthetic pathway may be used in combination, such that a series of reactions occur to produce a desired PUFA.
- expression cassette(s) encoding elongase, delta-5 desaturase, delta-17 desaturase and delta-4 desaturase activity would enable a host cell that naturally produces GLA, to instead produce DHA (such that GLA is converted to DGLA by an elongase; DGLA may then be converted to ARA by a delta-5 desaturase; ARA is then converted to EPA by a delta-17 desaturase, which may in turn be converted to DPA by an elongase; and DPA would be converted to DHA by a delta-4 desaturase).
- expression of the delta-8 desaturase of the invention enables the indirection production of ARA, EPA, DPA and/or DHA as down-stream PUFAs, if subsequent desaturase and elongation reactions are catalyzed.
- the host cell is an oleaginous yeast
- expression cassettes encoding each of the enzymes necessary for PUFA biosynthesis will need to be introduced into the organism, since naturally produced PUFAs in these organisms are limited to 18:2 fatty acids (i.e., LA), and less commonly, 18:3 fatty acids (i.e., ALA).
- substrate feeding may be required.
- Vectors or DNA cassettes useful for the transformation of suitable microbial host cells are well known in the art. The specific choice of sequences present in the construct is dependent upon the desired expression products (supra), the nature of the host cell and the proposed means of separating transformed cells versus non- transformed cells. Typically, however, the vector or cassette contains sequences directing transcription and translation of the relevant gene(s), a selectable marker and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene that controls transcriptional initiation and a region 3 1 of the DNA fragment that controls transcriptional termination. It is most preferred when both control regions are derived from genes from the transformed host cell, although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.
- Initiation control regions or promoters which are useful to drive expression of desaturase and/or elongase ORFs in the desired microbial host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of directing expression of these genes in the selected host cell is suitable for the present invention. Expression in a microbial host cell can be accomplished in a transient or stable fashion. Transient expression can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest. Stable expression can be achieved by the use of a constitutive promoter operably linked to the gene of interest. As an example, when the host cell is yeast, transcriptional and translational regions functional in yeast cells are provided, particularly from the host species.
- the transcriptional initiation regulatory regions can be obtained, for example, from: 1.) genes in the glycolytic pathway, such as alcohol dehydrogenase, glyceraldehyde-3-phosphate-dehydrogenase (WO 2005/003310), phosphoglycerate mutase (WO 2005/003310), fructose-bisphosphate aldolase (WO 2005/049805), phosphoglucose-isomerase, phosphoglycerate kinase, glycerol-3-phosphate O- acyltransferase (see U.S. Patent Application No.
- regulatable genes such as acid phosphatase, lactase, metallothionein, glucoamylase, the translation elongation factor EF1- ⁇ (TEF) protein (U.S. 6,265,185), ribosomal protein S7 (U.S. 6,265,185), etc.
- TEF translation elongation factor EF1- ⁇
- ribosomal protein S7 U.S. 6,265,185
- Any one of a number of regulatory sequences can be used, depending upon whether constitutive or induced transcription is desired, the efficiency of the promoter in expressing the ORF of interest, the ease of construction and the like. Nucleotide sequences surrounding the translational initiation codon 'ATG' have been found to affect expression in yeast cells.
- the nucleotide sequences of exogenous genes can be modified to include an efficient yeast translation initiation sequence to obtain optimal gene expression. For expression in yeast, this can be done by site-directed mutagenesis of an inefficiently expressed gene by fusing it in-frame to an endogenous yeast gene, preferably a highly expressed gene.
- Yarrowia lipolytica one can determine the consensus translation initiation sequence in the host and engineer this sequence into heterologous genes for their optimal expression in the host of interest.
- the termination region can be derived from the 3' region of the gene from which the initiation region was obtained or from a different gene.
- a large number of termination regions are known and function satisfactorily in a variety of hosts (when utilized both in the same and different genera and species from where they were derived).
- the termination region usually is selected more as a matter of convenience rather than because of any particular property.
- the termination region is derived from a yeast gene, particularly Saccharomyces, Schizosaccharomyces, Candida, Yarrowia or Kluyveromyces.
- the 3'-regions of mammalian genes encoding ⁇ -interferon and ⁇ -2 interferon are also known to function in yeast. Termination control regions may also be derived from various genes native to the preferred hosts.
- a termination site may be unnecessary; however, it is most preferred if included.
- a termination site may be unnecessary; however, it is most preferred if included.
- merely inserting a gene into a cloning vector does not ensure that it will be successfully expressed at the level needed.
- many specialized expression vectors have been created by manipulating a number of different genetic elements that control aspects of transcription, translation, protein stability, oxygen limitation and secretion from the host cell.
- some of the molecular features that have been manipulated to control gene expression include: 1.) the nature of the relevant transcriptional promoter and terminator sequences; 2.) the number of copies of the cloned gene and whether the gene is plasmid-borne or integrated into the genome of the host cell; 3.) the final cellular location of the synthesized foreign protein; 4.) the efficiency of translation in the host organism; 5.) the intrinsic stability of the cloned gene protein within the host cell; and 6.) the codon usage within the cloned gene, such that its frequency approaches the frequency of preferred codon usage of the host cell.
- modifications are encompassed in the present invention, as means to further optimize expression of the PUFA biosynthetic pathway enzymes.
- the DNA encoding a desaturase or elongase polypeptide suitable for expression in an oleaginous yeast is placed in a plasmid vector capable of autonomous replication in a host cell; or, it is directly integrated into the genome of the host cell. Integration of expression cassettes can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination within the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.
- the preferred method of expressing genes in Yarrowia lipolytica is by integration of linear DNA into the genome of the host; and, integration into multiple locations within the genome can be particularly useful when high level expression of genes are desired. Toward this end, it is desirable to identify a sequence within the genome that is present in multiple copies.
- preferred alternate loci include: the Ura3 locus (GenBank Accession No. AJ306421), the Leu2 gene locus (GenBank Accession No. AF260230), the Lys5 gene (GenBank Accession No. M34929), the Aco2 gene locus (GenBank Accession No. AJ001300), the Pox3 gene locus (Pox3: GenBank Accession No. XP_503244; or, Aco3: GenBank Accession No. AJ001301), the delta-12 desaturase gene locus (SEQ ID NO:23), the Lip1 gene locus (GenBank Accession No. Z50020) and/or the Lip2 gene locus (GenBank Accession No. AJ012632).
- the Ura3 gene can be used repeatedly in combination with 5-fluoroorotic acid ( ⁇ -fluorouracil- ⁇ -carboxylic acid monohydrate; "5-FOA”) selection (infra), to readily permit genetic modifications to be integrated into the Yarrowia genome in a facile manner.
- 5-fluoroorotic acid ⁇ -fluorouracil- ⁇ -carboxylic acid monohydrate; "5-FOA” selection (infra) selection (infra) selection (infra)
- each vector has a different means of selection and should lack homology to the other constructs to maintain stable expression and prevent reassortment of elements among constructs. Judicious choice of regulatory regions, selection means and method of propagation of the introduced construct can be experimentally determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products. Constructs comprising the gene of interest may be introduced into a host cell by any standard technique.
- transformation e.g., lithium acetate transformation [Methods in Enzymology, 194:186-187 (1991)]
- protoplast fusion e.g., bolistic impact, electroporation, microinjection, or any other method that introduces the gene of interest into the host cell.
- More specific teachings applicable for oleaginous yeasts include U.S. 4,880,741 and U.S.
- a host cell that has been manipulated by any method to take up a DNA sequence (e.g., an expression cassette) will be referred to as “transformed” or “recombinant” herein.
- the transformed host will have at least one copy of the expression construct and may have two or more, depending upon whether the gene is integrated into the genome, amplified or is present on an extrachromosomal element having multiple copy numbers.
- the transformed host cell can be identified by various selection techniques, as described in WO2004/101757. Preferred selection methods for use herein are resistance to kanamycin, hygromycin and the amino glycoside G418, as well as ability to grow on media lacking uracil, leucine, lysine, tryptophan or histidine.
- 5-FOA is used for selection of yeast Ura- mutants.
- the compound is toxic to yeast cells that possess a functioning URA3 gene encoding orotidine 5'-monophosphate decarboxylase (OMP decarboxylase); thus, based on this toxicity, 5-FOA is especially useful for the selection and identification of Ura " mutant yeast strains (Bartel, P. L.
- Ura3 gene in combination with 5-FOA selection
- the Ura3 gene can be used as a selection marker in multiple rounds of transformation.
- substrates suitable for the recombinantly expressed desaturases and/or elongases may be produced by the host either naturally or transgenically, or they may be provided exogenously.
- the host is selected or obtained by removing or inhibiting delta-15 or omega-3 type desaturase activity that permits conversion of LA to ALA.
- the endogenous desaturase activity can be reduced or eliminated by, for example: 1.) providing a cassette for transcription of antisense sequences to the delta-15 desaturase transcription product; 2.) disrupting the delta- 15 desaturase gene through insertion, substitution and/or deletion of all or part of the target gene; or 3.) using a host cell which naturally has [or has been mutated to have] low or no delta-15 desaturase activity. Inhibition of undesired desaturase pathways can also be accomplished through the use of specific desaturase inhibitors such as those described in U.S. 4,778,630.
- omega-3 fatty acids it may be desirable to maximize production of omega-3 fatty acids (and minimize synthesis of omega-6 fatty acids).
- a host microorganism wherein the delta-12 desaturase activity that permits conversion of oleic acid to LA is removed or inhibited, using any of the means described above (see also e.g., WO 2004/104167, herein incorporated entirely by reference).
- appropriate expression cassettes would be introduced into the host, along with appropriate substrates (e.g., ALA) for conversion to omega-3 fatty acid derivatives of ALA (e.g., STA, ETrA, ETA, EPA, DPA, DHA).
- Additional copies of desaturase and elongase genes may be introduced into the host to increase the output of omega-3 and/or omega-6 fatty acid biosynthetic pathways.
- Expression of the desaturase or elongase genes also can be increased at the transcriptional level through the use of a stronger promoter (either regulated or constitutive) to cause increased expression, by removing/deleting destabilizing sequences from either the mRNA or the encoded protein, or by adding stabilizing sequences to the mRNA (U.S. 4,910,141).
- Yet another approach to increase expression of the desaturase or elongase genes is to increase the translational efficiency of the encoded mRNAs by replacement of codons in the native gene with those for optimal gene expression in the selected host microorganism.
- Techniques To Down-Regulate Undesirable Biosvnthetic Pathways Conversely, biochemical pathways competing with the omega-3 and/or omega-6 fatty acid biosynthetic pathways for energy or carbon, or native PUFA biosynthetic pathway enzymes that interfere with production of a particular PUFA end-product, may be eliminated by gene disruption or down-regulated by other means (e.g., antisense mRNA).
- a foreign DNA fragment (typically a selectable marker gene) is inserted into the structural gene to be disrupted in order to interrupt its coding sequence and thereby functionally inactivate the gene. Transformation of the disruption cassette into the host cell results in replacement of the functional native gene by homologous recombination with the non-functional disrupted gene (see, for example: Hamilton et al. J. Bacteriol. 171 :4617-4622 (1989); Balbas et al. Gene 136:211-213 (1993); Gueldener et al. Nucleic Acids Res. 24:2519-2524 (1996); and Smith et al. Methods MoI. Cell. Biol. 5:270-277 (1996)).
- Antisense technology is another method of down-regulating genes when the sequence of the target gene is known. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the anti- sense strand of RNA will be transcribed. This construct is then introduced into the host cell and the antisense strand of RNA is produced. Antisense RNA inhibits gene expression by preventing the accumulation of mRNA that encodes the protein of interest.
- the person skilled in the art will know that special considerations are associated with the use of antisense technologies in order to reduce expression of particular genes. For example, the proper level of expression of antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan.
- the present invention provides methods whereby genes encoding key enzymes in the biosynthetic pathways are introduced into oleaginous yeasts for the production of omega-3 and/or omega-6 fatty acids. It will be particularly useful to express these genes in oleaginous yeasts that do not naturally possess omega-3 and/or omega-6 fatty acid biosynthetic pathways and coordinate the expression of these genes, to maximize production of preferred PUFA products using various means for metabolic engineering of the host organism.
- Microbial host cells for production of omega fatty acids may include microbial hosts that grow on a variety of feedstocks, including simple or complex carbohydrates, organic acids and alcohols, and/or hydrocarbons over a wide range of temperature and pH values.
- Preferred microbial hosts are oleaginous yeasts. These organisms are naturally capable of oil synthesis and accumulation, wherein the oil can comprise greater than about 25% of the cellular dry weight, more preferably greater than about 30% of the cellular dry weight, and most preferably greater than about 40% of the cellular dry weight.
- Genera typically identified as oleaginous yeast include, but are not limited to: Yarrowia, Candida, Rhodotorula, Rhodosporidium, Cryptococcus, Trichosporon and Lipomyces. More specifically, illustrative oil- synthesizing yeasts include: Rhodosporidium toruloides, Lipomyces starkeyii, L. lipoferus, Candida revkaufi, C.
- Yarrowia lipolytica (formerly classified as Candida lipolytica).
- Most preferred is the oleaginous yeast Yarrowia lipolytica; and, in a further embodiment, most preferred are the Y. lipolytica strains designated as ATCC #20362, ATCC #8862, ATCC #18944, ATCC #76982 and/or LGAM S(7)1 (Papanikolaou S., and Aggelis G., Bioresour. Technol. 82(1):43-9 (2002)).
- lipolytica have been used for the manufacture and production of: isocitrate lyase (DD259637); lipases (SU1454852, WO2001083773, DD279267); polyhydroxyalkanoates (WO2001088144); citric acid (RU2096461 , RU2090611, DD285372, DD285370, DD275480, DD227448, PL160027); erythritol (EP770683); 2-oxoglutaric acid (DD267999); ⁇ -decalactone (U.S. 6,451 ,565, FR2734843); ⁇ -dodecalatone (EP578388); and pyruvic acid (JP09252790).
- Microbial Fermentation Processes For PUFA Production The transformed microbial host cell is grown under conditions that optimize desaturase and elongase activities and produce the greatest and the most economical yield of the preferred PUFAs.
- media conditions that may be optimized include the type and amount of carbon source, the type and amount of nitrogen source, the carbon-to-nitrogen ratio, the oxygen level, growth temperature, pH, length of the biomass production phase, length of the oil accumulation phase and the time of cell harvest.
- Microorganisms of interest such as oleaginous yeast are grown in complex media (e.g., yeast extract-peptone-dextrose broth (YPD)) or a defined minimal media that lacks a component necessary for growth and thereby forces selection of the desired expression cassettes (e.g., Yeast Nitrogen Base (DIFCO Laboratories, Detroit, Ml)). Fermentation media in the present invention must contain a suitable carbon source.
- complex media e.g., yeast extract-peptone-dextrose broth (YPD)
- a defined minimal media that lacks a component necessary for growth and thereby forces selection of the desired expression cassettes
- Fermentation media in the present invention must contain a suitable carbon source.
- Suitable carbon sources may include, but are not limited to: monosaccharides (e.g., glucose, fructose), disaccharides (e.g., lactose, sucrose), oligosaccharides, polysaccharides (e.g., starch, cellulose or mixtures thereof), sugar alcohols (e.g., glycerol) or mixtures from renewable feedstocks (e.g., cheese whey permeate, comsteep liquor, sugar beet molasses, barley malt).
- monosaccharides e.g., glucose, fructose
- disaccharides e.g., lactose, sucrose
- oligosaccharides e.g., polysaccharides (e.g., starch, cellulose or mixtures thereof)
- sugar alcohols e.g., glycerol
- renewable feedstocks e.g., cheese whey permeate, comsteep liquor, sugar
- carbon sources may include alkanes, fatty acids, esters of fatty acids, monoglycerides, diglycerides, triglycerides, phospholipids and various commercial sources of fatty acids including vegetable oils (e.g., soybean oil) and animal fats.
- the carbon source may include one-carbon sources (e.g., carbon dioxide, methanol, formaldehyde, formate and carbon-containing amines) for which metabolic conversion into key biochemical intermediates has been demonstrated.
- the source of carbon utilized in the present invention may encompass a wide variety of carbon-containing sources and will only be limited by the choice of the host organism.
- carbon sources and mixtures thereof are expected to be suitable in the present invention
- preferred carbon sources are sugars and/or fatty acids. Most preferred is glucose and/or fatty acids containing between 10-22 carbons.
- Nitrogen may be supplied from an inorganic (e.g., (NH ⁇ SO ⁇ or organic source (e.g., urea or glutamate).
- the fermentation media must also contain suitable minerals, salts, cofactors, buffers, vitamins and other components known to those skilled in the art suitable for the growth of the microorganism and promotion of the enzymatic pathways necessary for PUFA production.
- Preferred growth media in the present invention are common commercially prepared media, such as Yeast Nitrogen Base (DIFCO Laboratories, Detroit, Ml). Other defined or synthetic growth media may also be used and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or fermentation science.
- a suitable pH range for the fermentation is typically between about pH 4.0 to pH 8.0, wherein pH 5.5 to pH 7.0 is preferred as the range for the initial growth conditions.
- the fermentation may be conducted under aerobic or anaerobic conditions, wherein microaerobic conditions are preferred.
- the PUFAs may be found in the host microorganism as free fatty acids or in esterified forms such as acylglycerols, phospholipids, sulfolipids or glycolipids, and may be extracted from the host cell through a variety of means well-known in the art.
- extraction techniques, quality analysis and acceptability standards for yeast lipids is that of Z. Jacobs (Critical Reviews in Biotechnology 12(5/6):463-491 (1992)).
- a brief review of downstream processing is also available by A. Singh and O. Ward (Adv. Appl. Microbiol. 45:271-312 (1997)).
- means for the purification of PUFAs may include extraction with organic solvents, sonication, supercritical fluid extraction (e.g., using carbon dioxide), saponification and physical means such as presses, or combinations thereof.
- solvents e.g., water
- supercritical fluid extraction e.g., using carbon dioxide
- saponification e.g., using carbon dioxide
- physical means such as presses, or combinations thereof.
- Eg5 and Eg 12 were each cloned into a Saccharomyces cerevisiae yeast expression vector (Example 5) for functional analysis via substrate feeding trials (Example 11). This demonstrated that both Eg5 and Eg 12 were able to desaturase EDA and ETrA to produce DGLA and ETA, respectively; Eg5 had significantly greater activity than Eg 12. Based on the confirmed delta-8 desaturase activity of Eg5 (SEQ ID NO:1 and
- Eg5 was codon-optimized for expression in Yarrowia lipolytica (Example 14), thereby resulting in the synthesis of a synthetic, functional codon- optimized delta-8 desaturase designated as "D8SF" (SEQ ID NOs:112 and 113).
- D8SF codon-optimized delta-8 desaturase of the invention in conjunction with a codon-optimized delta-9 elongase (derived from lsochrysis galbana (GenBank Accession No. 390174)) in Y. lipolytica enabled synthesis of 6.4% DGLA, with no co-synthesis of GLA (Example 16).
- Yarrowia lipolytica strains ATCC #20362, #76982 and #90812 were purchased from the American Type Culture Collection (Rockville, MD). Y. lipolytica strains were usually grown at 28 °C on YPD agar (1 % yeast extract, 2% bactopeptone, 2% glucose, 2% agar).
- Transformation of Yarrowia lipolytica was performed according to the method of Chen, D. C. et al. (Appl. Microbiol Biotechnol. 48(2):232-235 (1997)), unless otherwise noted. Briefly, Yarrowia was streaked onto a YPD plate and grown at 30 ° C for approximately 18 hr. Several large loopfuls of cells were scraped from the plate and resuspended in 1 m!_ of transformation buffer containing: 2.25 ml_ of 50% PEG, average MW 3350; 0.125 ml_ of 2 M Li acetate, pH 6.0; 0.125 ml_ of 2 M DTT; and 50 ⁇ g sheared salmon sperm DNA.
- MM minimal medium
- DIFCO yeast nitrogen base
- 5-fluorouracil-6-carboxylic acid monohydrate selection media comprising: 0.17% yeast nitrogen base (DIFCO Laboratories, Detroit, Ml) without ammonium sulfate or amino acids, 2% glucose, 0.1% proline, 75 mg/L uracil, 75 mg/L uridine, 900 mg/L FOA (Zymo Research Corp., Orange, CA) and 20 g/L agar. Fatty Acid Analysis Of Yarrowia lioolvtica
- fatty acid analysis For fatty acid analysis, cells were collected by centrifugation and lipids were extracted as described in Bligh, E. G. & Dyer, W. J. (Can. J. Biochem. Physiol. 37:911-917 (1959)). Fatty acid methyl esters were prepared by transesterification of the lipid extract with sodium methoxide (Roughan, G., and Nishida I. Arch Biochem Biophys. 276(1):38-46 (1990)) and subsequently analyzed with a Hewlett-Packard 6890 GC fitted with a 30-m X 0.25 mm (i.d.) HP-INNOWAX (Hewlett-Packard) column. The oven temperature was from 170 °C (25 min hold) to 185 °C at 3.5
- Yarrowia culture (3 mL) was harvested, washed once in distilled water, and dried under vacuum in a Speed-Vac for 5-10 min.
- Sodium methoxide (100 ⁇ l of 1 %) was added to the sample, and then the sample was vortexed and rocked for 20 min. After adding 3 drops of 1 M NaCI and 400 ⁇ l hexane, the sample was vortexed and spun. The upper layer was removed and analyzed by GC as described above.
- delta-8 desaturase gene of Euglena gracilis (SEQ ID NOs:5 and 6, GenBank Accession No. AAD45877) in Yarrowia lipolytica
- the codon usage of the delta-8 desaturase gene was optimized for expression in Y. lipolytica.
- a codon-optimized delta-8 desaturase gene (designated "D8S-1", SEQ ID NO:48) was designed, based on the published sequence of Euglena gracilis (SEQ ID NO:5), according to the Yarrowia codon usage pattern (WO 2004/101753), the consensus sequence around the 'ATG' translation initiation codon, and the general rules of RNA stability (Guhaniyogi, G. and J.
- the codon-optimized delta-8 desaturase gene was synthesized as follows. First, thirteen pairs of oligonucleotides were designed to extend the entire length of the codon-optimized coding region of the E. gracilis delta-8 desaturase gene (e.g., D8-1A, D8-1 B, D8-2A, D8-2B, D8-3A, D8-3B, D8-4A, D8-4B, D8-5A, D8-5B, D8-6A, D8-6B, D8-7A, D8-7B, D8-8A, D8-8B, D8-9A, D8-9B, D8-10A, D8-10B, D8-11A, D8- 11 B, D8-12A, D8-12B, D8-13A and D8-13B, corresponding to SEQ ID NOs:49-74).
- primers D8-1A, D8-3B, D8-7A, D8-9B and D8-13B SEQ ID NOs:49, 54, 60, 65 and 74 also introduced Ncol, BgIII, Xho1, Sacl and Not1 restriction sites, respectively, for subsequent subcloning.
- Each oligonucleotide (100 ng) was phosphorylated at 37 °C for 1 hr in a volume of 20 ⁇ l containing 50 mM Tris-HCI (pH 7.5), 10 mM MgC ⁇ , 10 mM DTT, 0.5 imM spermidine, 0.5 mM ATP and 10 U of T4 polynucleotide kinase.
- Each pair of sense and antisense oligonucleotides was mixed and annealed in a thermocycler using the following parameters: 95 °C (2 min), 85 °C (2 min), 65 °C (15 min), 37 °C
- D8-1A (SEQ ID NO:49) was annealed to D8-1 B (SEQ ID NO:50) to produce the double-stranded product "D8- 1AB”.
- D8-2A (SEQ ID NO:51) was annealed to D8-2B (SEQ ID NO:52) to produce the double-stranded product "D8-2AB", etc.
- Pool 1 comprised D8-1AB, D8-2AB and D8- 3AB
- Pool 2 comprised D8-4AB, D8-5AB and D8-6AB
- Pool 3 comprised D8-7AB, D8-8AB, and D8-9AB
- Pool 4 comprised D8-10AB, D8-11AB, D8- 12AB and D8-13AB.
- Each pool of annealed oligonucleotides was mixed in a volume of 20 ⁇ l with 10 U of T4 DNA ligase and the ligation reaction was incubated overnight at 16 °C.
- the product of each ligation reaction was then used as template to amplify the designed DNA fragment by PCR.
- the ligated "Pool 1" mixture i.e., D8-1AB, D8-2AB and D8-3AB
- oligonucleotides D8-1F SEQ ID NO:75
- D8-3R SEQ ID NO:76
- the PCR amplification was carried out in a 50 ⁇ l total volume, comprising PCR buffer containing 10 mM KCI, 10 mM (NH4)2SO4, 20 mM Tris-HCI (pH 8.75), 2 mM MgSO 4 , 0.1% Triton X-
- the second portion of the codon-optimized delta-8 desaturase gene was amplified similarly by PCR and cloned into pGEM-T-easy vector to generate pT8(4- 6).
- the third portion of the codon-optimized delta-8 desaturase gene was amplified similarly by PCR and cloned into pGEM-T-easy vector to generate pT8(7- 9).
- the fourth portion of the codon-optimized delta-8 desaturase gene was amplified similarly by PCR and cloned into pGEM-T-easy vector to generate pT8(10-13).
- E. coli was transformed separately with pT8(1-3), pT8(4-6), pT8(7-9) and pT8(10-13) and the plasmid DNA was isolated from ampicillin-resistant transformants.
- Plasmid DNA was purified and digested with the appropriate restriction endonucleases to liberate the 309 bp Ncol/Bglll fragment of pT8(1-3) (SEQ ID NO:83), the 321 bp Bglll/Xhol fragment of pT8(4-6) (SEQ ID NO:84), the 264 bp Xhol/Sacl fragment of pT8(7-9) (SEQ ID NO:85) and the 369 bp Sac1/Not1 fragment of pT8(10-13) (SEQ ID NO:86).
- E. gracilis the second amino acid of D8S-1 was changed from 'K' to ⁇ ' in order to add the ⁇ /col site around the translation initiation codon.
- Another version of the synthesized gene was constructed by in vitro mutagenesis (Stratagene, San Diego, CA) using pDMW240 as a template and oligonucleotides ODMW390 (SEQ ID NO:87) and ODMW391 (SEQ ID NO:88) as primers.
- the resulting plasmid was designated pDMW255 ( Figure 5B).
- the synthetic delta-8 desaturase gene in pDMW255 was designated as "D8S-2" and the amino acid sequence is exactly the same as the sequence depicted in SEQ ID NO:5.
- Yarrowia lipolytica strainATCC #76982(Leu-) was transformed with pDMW240 and pDMW255, respectively, as described in the General Methods.
- Yeast containing the recombinant constructs pDMW240 and pDMW255 i.e., containing D8S-1 and D8S-2 respectively
- EDA EDA
- 20:2(11 ,14) single colonies of transformant V.
- lipolytics containing either pDMW240 or pDMW255 were grown in 3 ml_ MM at 30 "C to an OD 6 Oo ⁇ 1 0-
- 100 ⁇ l of cells were then subcultured in 3 mL MM containing 10 ⁇ g of EDA substrate for about 24 hr at 30 0 C.
- the cells were collected by centrifugation, lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC.
- D8S-1 and D8S-2 were not functional and could not desaturate EDA.
- the chimeric D8S-1 ::XPR terminator and D8S-2::XPR terminator genes are shown in SEQ ID NOs:89 and 90, respectively.
- Euglena gracilis Growth Conditions Lipid Profile And mRNA Isolation Euglena gracilis was obtained from Dr. Richard Triemer's lab at Michigan State University (East Lansing, Ml). From 10 mL of actively growing culture, a 1 mL aliquot was transferred into 250 mL of Euglena gracilis (Eg) Medium in a 500 mL glass bottle. Eg medium was made by combining: 1 g of sodium acetate, 1 g of beef extract (U126-01 , Difco Laboratories, Detroit, Ml), 2 g of Bacto ® Tryptone
- TMSH trimethylsulfonium hydroxide
- Fatty acid methyl esters (5 ⁇ L injected from hexane layer) were separated and quantified using a Hewlett- Packard 6890 Gas Chromatograph fitted with an Omegawax 320 fused silica capillary column (Catalog #24152, Supelco Inc.). The oven temperature was programmed to hold at 220 0 C for 2.7 min, increase to 240 °C at 20 °C /min and then hold for an additional 2.3 min. Carrier gas was supplied by a Whatman hydrogen generator. Retention times were compared to those for methyl esters of standards commercially available (Catalog #U-99-A, Nu-Chek Prep, Inc.) and the resulting chromatogram is shown in Figure 1. The remaining 2 week culture (240 mL) was pelleted by centrifugation at
- RNA STAT-60TM reagent TEL-TEST, Inc., Friendswood, TX
- RNA STAT-60TM reagent TEL-TEST, Inc., Friendswood, TX
- mRNA Purification Kit Amersham Biosciences, Piscataway, NJ
- EXAMPLE 3 cDNA Synthesis And PCR Of Euglena gracilis DeIta-8 Desaturase cDNA was synthesized from 765 ng of mRNA (Example 2) using the SuperscriptTM Choice System for cDNA synthesis (InvitrogenTM Life Technologies, Carlsbad, CA) with the provided oligo(dT) primer according to the manufacturer's protocol. The synthesized cDNA was dissolved in 20 ⁇ l_ of water.
- the Euglena gracilis delta-8 desaturase was amplified from cDNA with oligonucleotide primers Eg5-1 (SEQ ID NO:8) and Eg3-3 (SEQ ID NO:9) using the conditions described below.
- cDNA (1 ⁇ l_) from the reaction described above was combined with 50 pmol of Eg5-1 , 50 pmol of Eg5-1 , 1 ⁇ L of PCR nucleotide mix (10 mM, Promega, Madison, Wl), 5 ⁇ L of 10X PCR buffer (Invitrogen), 1.5 ⁇ L of MgCI 2 (50 mM, Invitrogen), 0.5 ⁇ L of Taq polymerase (Invitrogen) and water to 50 ⁇ L.
- the reaction conditions were 94 0 C for 3 min followed by 35 cycles of 94 0 C for 45 sec, 55 0 C for 45 sec and 72 0 C for 1 min.
- the PCR was finished at 72 0 C for 7 min and then held at 4 0 C.
- the PCR reaction was analyzed by agarose gel electrophoresis on 5 ⁇ L and a DNA band with molecular weight around 1.3 kB was observed. The remaining 45 ⁇ L of product was separated by agarose gel electrophoresis and the DNA band was purified using the ZymocleanTM Gel DNA Recovery Kit (Zymo
- the N-terminus has multiple amino acid changes.
- the published amino acid sequences have an extra serine between L9 and P10 and amino acids from position T12-T16 are completely different (TIDGT' to 'QLMEQ'). These changes result from multiple insertions in the DNA sequence of the published sequence and this causes 3 shifts in frame in this region. These changes are only 10 amino acids away from the putative cytochrome b 5 domain ('HPGG').
- SEQ ID NO:4 has a single amino acid change as compared to SEQ ID NO:2 (T278 to A).
- SEQ ID NO:2 the functional delta-8 desaturase protein sequence from Euglena gracilis claimed in this invention
- SEQ ID NOs:6 and 7 the published sequences
- the yeast episomal plasmid (YEp)-type vector pRS425 (Christianson et al., Gene, 110:119-22 (1992)) contains sequences from the Saccharomyces cerevisiae 2 ⁇ endogenous plasmid, a LEU2 selectable marker and sequences based on the backbone of a multifunctional phagemid, pBluescript Il SK +.
- the S. cerevisiae strong, constitutive glyceraldehyde-3-phosphate dehydrogenase (GPD) promoter was cloned between the Sacll and Spel sites of pRS425 in the same way as described in Jia et al.
- Eg5 SEQ ID NO:1
- Eg 12 SEQ ID NO:3 were released from the pGEM ® - T Easy vectors described in Example 2 by digestion with ⁇ /ofl and cloned into the Not ⁇ site of pY-75 to produce pY89-5 and pY89-12, respectively.
- delta-8 desaturases i.e., Eg5 [SEQ ID NO:1] and Eg12 [SEQ ID NO:3]
- Eg5 [SEQ ID NO:1] and Eg12 [SEQ ID NO:3] were cloned behind a strong constitutive promoter for expression in S. cerevisiae.
- a map of pY89-5 is shown in Figure 3A.
- a starting plasmid pKS123 (WO 02/08269, the contents of which are hereby incorporated by reference) contains the hygromycin B phosphotransferase gene (HPT) [Gritz, L. and Davies, J. Gene 25:179-188 (1983)], flanked by the T7 promoter and transcription terminator (T7prom/hpt/T7term cassette), and a bacterial origin of replication (ori) for selection and replication in bacteria (e.g., E. coli).
- HPT hygromycin B phosphotransferase gene
- T7prom/hpt/T7term cassette flanked by the T7 promoter and transcription terminator
- ori bacterial origin of replication
- pKS123 also contains the hygromycin B phosphotransferase gene, flanked by the 35S promoter (Odell et al., Nature 313:810-812 (1985)) and NOS 3' transcription terminator (Depicker et al., J. MoI. Appl. Genet. 1 :561 :570 (1982))
- pKS123 also contains a Not ⁇ restriction site, flanked by the promoter for the ⁇ ' subunit of ⁇ - conglycinin (Beachy et al., EMBO J. 4:3047-3053 (1985)) and the 3 J transcription termination region of the phaseolin gene (Doyle, J.J. et al. J. Biol. Chem. 261:9228-
- Vector pKR72 is a derivative of pKS123, wherein the H/ ⁇ dlll fragment containing the ⁇ -conglycinin/ ⁇ /ofl/phaseolin cassette has been inverted and a sequence (SEQ ID NO:14) containing Sbf ⁇ , Fse ⁇ and ⁇ s/WI restriction enzyme sites was introduced between the Hind ⁇ and BamHl sites in front of the ⁇ -conglycinin promoter.
- Vector pKS121 (WO 02/00904) contains a Not ⁇ site flanked by the Kunitz soybean Trypsin Inhibitor (KTi) promoter (Jofuku et al., Plant Ce// 1 :1079-1093 (1989)) and the KTi 3 J termination region, the isolation of which is described in U.S.
- KTi Kunitz soybean Trypsin Inhibitor
- Vector pKR457 is a derivative of pKS121 where the restriction sites upstream and downstream of the Kti/ ⁇ /ofl/Kti3' cassette have been altered through a number of subcloning steps.
- Vector pKR457 also contains the Soy albumin transcription terminator downstream of the Kti terminator to lengthen and strengthen termination of transcription.
- the BamHI site upstream of the Kti promoter in pKS121 was removed and a new sequence (SEQ ID
- the albumin transcription terminator was previously amplified from soy genomic DNA using primer oSalb-12 (SEQ ID NO:19; designed to introduce BamHI, Xba ⁇ and Bsi ⁇ N ⁇ sites at the 3' end of the terminator), and primer oSalb-13 (SEQ ID NO:20; designed to introduce BamH ⁇ sites at the 5' end of the terminator). After PCR, sites at ends were modified by sub-cloning through various intermediate vectors to finally produce the sequence shown in SEQ ID NO:5.
- Eg5 (SEQ ID NO: 1) was released from the pGEM ® - T Easy by digestion with Not ⁇ and cloned into the Not ⁇ site of pKR457 to produce pKR680. Plasmid pKR680 was then digested with Bsi ⁇ N ⁇ and the fragment containing Eg5 (SEQ ID NO:1) was cloned into the Ss/WI site of pKR324 (WO 2004/071467) to produce pKR681.
- the delta-8 desaturase (Eg5; SEQ ID NO:1) could be co-expressed with the Mortierella alpina elongase behind strong, seed-specific promoters.
- a map of pKR681 is shown in Figure 3B.
- soybean annexin and BD30 promoters were isolated with the Universal GenomeWalker system (Clontech) according to its user manual (PT3042-1).
- PT3042-1 Universal GenomeWalker system
- samples of soybean genomic DNA were digested with Dral, EcoRV, PvuW and SM separately for two hrs. After DNA purification, the digested genomic DNAs were ligated to the GenomeWalker adaptors AP 1 and AP2.
- GSP1 SEQ ID NO:21
- GSP2 SEQ ID NO:22
- the AP1 and the GSP1 primers were used in the 1 st round PCR using the conditions defined in the GenomeWalker system protocol. Cycle conditions were 94 °C for 4 min; 94 °C for 2 sec and 72 °C for 3 min, 7 cycles; 94 °C for 2 sec and 67 0 C for 3 min, 32 cycles; 67 0 C for 4 min.
- the products from the first run PCR were diluted 50-fold. One microliter of the diluted products were used as templates for the 2 nd PCR with primers AP2 and GSP2.
- Cycle conditions were 94 0 C for 4 min; 94 °C for 2 sec and 72 °C for 3 min, 5 cycles; 94 0 C for 2 sec and 67 °C for
- a 2.1 kB genomic fragment was amplified and isolated from the EcoRV-digested GenomeWalker library. The genomic fragment was digested with BamH I and Sal I and cloned into Bluescript KS + vector for sequencing.
- the DNA sequence of this 2012 bp soybean annexin promoter fragment is set forth in SEQ ID NO:29. Based on this sequence, two oligonucleotides with either BamH I or ⁇ /ofl sites at the 5' ends were designed to re- amplify the promoter (i.e., SEQ ID NOs:30 and 31).
- GSP3 SEQ ID NO:23
- GSP4 SEQ ID NO:24
- a modified touchdown PCR protocol was used, wherein cycle conditions were: 94 0 C for 4 min; 94 °C for 2 sec and 74 °C for 3 min, 6 cycles in which annealing temperature drops 1 0 C every cycle; 94 0 C for 2 sec and 69 °C for 3 min, 32 cycles; 69 0 C for 4 min.
- the products from the 1 st run PCR were diluted 50-fold.
- One microliter of the diluted products were used as templates for the 2 nd PCR with primers AP2 and GSP4.
- Cycle conditions were: 94 °C for 4 min; 94 0 C for 2 sec and 74 0 C for 3 min, 6 cycles in which annealing temperature drops 1 0 C every cycle; 94 0 C for 2 sec and 69 0 C for 3 min, 20 cycles; 69 0 C for 3 min.
- a 1.5 kB genomic fragment was amplified and isolated from the Pvt/ll-digested GenomeWalker library. The genomic fragment was digested with BamH ⁇ and Sa/I and cloned into Bluescript KS + vector for sequencing. DNA sequencing determined that this genomic fragment contained a 1408 bp soybean BD30 promoter sequence (SEQ ID NO:25).
- the re-amplified annexin and BD30 promoter fragments were digested with BamH ⁇ and Not ⁇ , purified and cloned into the BamH ⁇ and Not ⁇ sites of plasmid pZBL115 to produce pJS88 and pJS89, respectively.
- the pZBL115 plasmid contains the origin of replication from pBR322, the bacterial HPT hygromycin resistance gene driven by a T7 promoter and T7 terminator, and a 35S promoter-HPT-Nos3' gene to serve as a hygromycin resistant plant selection marker. The M.
- alpina delta-6 desaturase gene was cloned into the Not ⁇ site of pJS88 and pJS89, in the sense orientation, to make plant expression cassettes pJS92 and pJS93, respectively. Based on the sequences of the soybean Glycinin Gy1 promoter sequence in
- GenBank accesion No. X15121
- the oligonucleotides set forth in SEQ ID NOs:27 and 28 were designed to amplify the soybean Glycinin Gy1 promoter (SEQ ID NO:26), wherein the primers had either BamhW or Not ⁇ sites at the 5' ends.
- the amplified soybean glycinin Gy1 promoter fragment was digested with BamYW and Not ⁇ , purified and cloned into the SamHI and Not ⁇ sites of plasmid pZBL115 (supra) to produce pZBL117.
- Plasmid pKR325 was generated from pKR72 (Example 5) by digestion with Hind ⁇ to remove the ⁇ con/ ⁇ /o£l/Phas3' cassette. Plasmid pKR680 (Example 5) was digested with Ss/WI and the fragment containing Eg5 (SEQ ID NO:1) was cloned into the Ss/WI site of pKR325 to produce pKR683.
- the KTi/ ⁇ /ofl/KTi3' cassette from pKS121 was PCR-amplified using primers oKTi ⁇ (SEQ ID NO:34) and oKTi ⁇ (SEQ ID NO:35), designed to introduce an Xba ⁇ and Bs/WI site at both ends of the cassette.
- the resulting PCR fragment was subcloned into the Xbal site of the cloning vector pUC19 to produce plasmid pKR124, thus adding a Pst ⁇ and Sbfl site at the 3' end of the Kti transcription terminator.
- the Sail fragment of pJS93 containing soy BD30 promoter (WO 01/68887) was combined with the SaIi fragment of pUC19 to produce pKR227, thus adding a Pst ⁇ and Sbf ⁇ site at the 5' end of the BD30 promoter.
- the BD30 3' transcription terminator was PCR-amplified from soy genomic DNA using primer oSBD30-1 (SEQ ID NO:36; designed to introduce an Not ⁇ site at the 5' end of the terminator) and primer oSBD30-2 (SEQ ID NO:37; designed to introduce a Ss/WI site at the 3' end of the terminator).
- the resulting PCR fragment was subcloned into the intermediate cloning vector pCR-Script AMP SK(+) (Stratagene) according the manufacturer's protocol to produce plasmid pKR251 r.
- the resulting fragment was ligated into the filled Ss/WI fragment from the vector backbone of pKR124 in a direction which added a Pst ⁇ and Sbf ⁇ site at the 5' end of the annexin promoter to produce pKR265.
- the annexin promoter was released from pKR265 by digestion with Sb ⁇ and Not ⁇ and was cloned into the Sbf ⁇ /Not ⁇ fragment of pKR256 (containing the BD30 3' transcription terminator, an ampicillin resistance gene and a bacterial ori region) to produce pKR268.
- the gene for the Saprolegnia diclina delta-17 desaturase was released from pKS203 (Pereira et a/., Biochem. J. 378:665-671 (2004)) by partial digestion with Not ⁇ , and was cloned into the Not ⁇ site of pKR268 to produce pKR271. In this way, the delta-17 desaturase was cloned as an expression cassette behind the annexin promoter with the BD30 transcription terminator.
- Plasmid pKR271 was then digested with Pst ⁇ and the fragment containing the Saprolegnia diclina delta-17 desaturase was cloned into the Sb ⁇ site of pKR683 to produce pKR685. In this way, the delta-8 desaturase could be co-expressed with the S. diclina delta-17 desaturase behind strong, seed-specific promoters.
- a map of pKR685 is shown in Figure 4A.
- M. alpina delta-6 desaturase (U.S. 5,968,809), M. alpina elongase (WO 00/12720) and M. alpina delta-5 desaturase (U.S. 6,075,183) were cloned into plasmid pKR274 (Figure 4B) behind strong, seed-specific promoters allowing for high expression of these genes in somatic soybean embryos and soybean seeds. All of these promoters exhibit strong tissue specific expression in the seeds of soybean. Plasmid pKR274 also contains the hygromycin B phosphotransferase gene (Gritz, L. and Davies, J.
- T7 RNA polymerase promoter cloned behind the T7 RNA polymerase promoter and followed by the T7 terminator (T7prom/HPT/T7term cassette) for selection of the plasmid on hygromycin B in certain strains of E. coli (e.g., NovaBlue(DE3) (Novagen, Madison, Wl), a strain that is lysogenic for lambda DE3 and carries the T7 RNA polymerase gene under lacUV ⁇ control).
- plasmid pKR274 contains a bacterial origin of replication (ori) functional in E. coli from the vector pSP72 (Stratagene).
- delta-6 desaturase was cloned behind the promoter for the ⁇ ' subunit of ⁇ -conglycinin (Beachy et al., EMBO J. 4:3047-3053 (1985)) followed by the 3' transcription termination region of the phaseolin gene (Doyle, JJ. et al. J. Biol. Chem. 261 :9228-9238 (1986)) ( ⁇ con/Mad6/Phas3' cassette).
- the delta-5 desaturase was cloned behind the Kunitz soybean Trypsin Inhibitor (KTi) promoter (Jofuku et al., Plant Cell 1 :1079-1093 (1989)), followed by the KTi 3' termination region, the isolation of which is described in U.S. 6,372,965 (KTi/Mad5/KTi3' cassette).
- the elongase was cloned behind the glycinin Gy 1 promoter followed by the pea leguminA2 3' termination region (Gy1/Maelo/legA2 cassette).
- the gene for the M. alpina delta-6 desaturase was PCR-amplified from pCGR5 (U.S. 5,968,809) using primers oCGR5-1 (SEQ ID NO:38) and oCGR5-2 (SEQ ID NO:39), which were designed to introduce Not ⁇ restriction enzyme sites at both ends of the delta-6 desaturase and an ⁇ /col site at the start codon of the reading frame for the enzyme.
- the resulting PCR fragment was subcloned into the intermediate cloning vector pCR-Script AMP SK(+) (Stratagene) according the manufacturer's protocol to produce plasmid pKR159.
- the Not ⁇ fragment of pKR159, containing the M. alpina delta-6 desaturase gene was cloned into Not ⁇ site of pZBL117 (Example 7) in the sense orientation to produce plant expression cassette pZBL119.
- Vector pKR197 was constructed by combining the Asc ⁇ fragment from plasmid pKS102 (WO 02/00905), containing the T7prom/hpt/T7term cassette and bacterial ori, with the Ascl fragment of plasmid pKR72 (Example 5), containing the ⁇ con/ ⁇ /ctf//Phas cassette. Plasmid pKR159 was digested with Not ⁇ to release the M. alpina delta-6 desaturase, which was, in turn, cloned into the Not ⁇ site of the soybean expression vector pKR197 to produce pKR269.
- the glycinin Gy1 promoter was amplified from pZBL119 using primer oSGly- 1 (SEQ ID NO:40; designed to introduce an SbWPsti site at the 5' end of the promoter) and primer oSGIy-2 (SEQ ID NO:41 ; designed to introduce a Not ⁇ site at the 3' end of the promoter).
- the resulting PCR fragment was subcloned into the intermediate cloning vector pCR-Script AMP SK(+) (Stratagene) according to the manufacturer's protocol to produce plasmid pSGIy12.
- the legA2 promoter was amplified from pea genomic DNA using primer LegPro ⁇ ' (SEQ ID NO:42; designed to introduce Xba ⁇ and ⁇ s/WI sites at the 5' end of the promoter) and primer LegPro3' (SEQ ID NO:43; designed to introduce a Not ⁇ site at the 3' end of the promoter).
- the legA2 transcription terminator was amplified from pea genomic DNA using primer LegTerm ⁇ ' (SEQ ID NO:44; designed to introduce Not ⁇ site at the 5' end of the terminator) and primer LegTerm3' (SEQ ID NO:45; designed to introduce Ss/WI and Xba ⁇ sites at the 3' end of the terminator).
- legA2/ ⁇ /ofl/legA23' cassette PCR fragment was subcloned into the intermediate cloning vector pCR-Script AMP SK(+) (Stratagene) according to the manufacturer's protocol to produce plasmid pKR140.
- Plasmid pKR142 was constructed by cloning the Bsi ⁇ N ⁇ fragment of pKR140 (containing the legA2/ ⁇ /ofl/legA23' cassette) into the Bs/WI site of pKR124
- the Pst ⁇ INot ⁇ fragment from plasmid pKR142 was then combined with the Pst ⁇ /Not ⁇ fragment of plasmid pSGIy12 (containing the glycininGyi promoter) to produce pKR263.
- the gene for the M. alpina delta-5 desaturase was amplified from pCGR4 (U.S. 6,075,183) using primers CGR4foward (SEQ ID NO:46) and CGR4reverse (SEQ ID NO:47) which were designed to introduce Not ⁇ restriction enzyme sites at both ends of the desaturase.
- the resulting PCR fragment was digested with Not ⁇ and cloned into the Not ⁇ site of vector pKR124 (Example 6) to produce pKR136.
- the Noti fragment containing the M. alpina elongase (Example 5) was cloned into the Not ⁇ site of vector pKR263 to produce pKR270.
- the Gy1/Maelo/legA2 cassette was released from plasmid pKR270 by digestion with Bs/WI and Sbfl and was cloned into the BsNWSb ⁇ sites of plasmid pKR269 (containing the delta-6 desaturase, the T7prom/hpt/T7term cassette and the bacterial ori region). This was designated as plasmid pKR272.
- KTi/Mad5/KTi3' cassette released from pKR136 by digestion with ⁇ s/WI, was then cloned into the Ss/W ⁇ site of pKR272 to produce pKR274 ( Figure 4B).
- Somatic Soybean Embryos And Soybean Seeds (Delta-17 Desaturase And
- the delta-17 desaturase from S. diclina could be cloned into a soy expression vector along with the delta-5 desaturase from M. alpina.
- the annexin/delta17/BD30 cassette of pKR271 could be released by digestion with a suitable restriction enzyme such as Pst ⁇ and cloned into a soy expression vector already carrying the M. alpina delta-5 desaturase behind a suitable promoter and a suitable selection marker such as hygromycin.
- the M. alpina delta-5 desaturase could be part of any suitable expression cassette described here. For instance, the Not ⁇ fragment containing the M.
- alpina delta-5 desaturase described above could be cloned into the Not ⁇ site of the Gy1/ ⁇ /ofl/legA2 cassette of pKR263.
- This Gy1/delta5/legA2 cassette could then be cloned into a vector containing a suitable selectable marker for soy transformation.
- Such a vector could be co-transformed into soy with pKR681 (Example 6) and transformants expression genes from both plasmids selected. In this way, EPA could be produced using the delta-8 pathway independent of a deIta-6 desaturase.
- PTA-6048 pY89-12 (identical to pY89-5, with the exception that the Eg 12 sequence was inserted instead of Eg5) and pY-75 (Example 5, negative control cloning vector [lacking Eg5 or Eg12]) were transformed into Saccharomyces cerevisiae BY4741 (ATCC #201388) using standard lithium acetate transformation procedures. Transformants were selected on DOBA media supplemented with CSM-leu (Qbiogene, Carlsbad, CA).
- Transformants from each plate were inoculated into 2 mL of DOB medium supplemented with CSM-leu (Qbiogene) and grown for 1 day at 30 0 C, after which 0.5 mL was transferred to the same medium supplemented with either EDA or EtrA to 1 mM. These were incubated overnight at 30 0 C, 250 rpm, pellets were obtained by centrifugation and dried under vacuum. Pellets were transesterified with 50 ⁇ l_ of TMSH and analyzed by GC as described in Example 1.
- the lipid profile obtained by GC analysis of clones fed EDA are shown in Table 5; and the lipid profile obtained by GC analysis of clones fed EtrA are shown in Table 6.
- delta-8 desaturases can be cloned into the soybean expression vectors such as those described in Example 6 and Example 8.
- a suitable delta-8 desaturase from an organism other than Euglena gracilis can be cloned using methods similar to, but not limited to, the methods described in Example 2 and Example 3.
- PCR primers designed to introduce Not ⁇ sites at the 5' and 3' ends of the delta-8 desaturase can be used to amplify the gene.
- the resulting PCR product can then be digested with ⁇ /ofl and cloned into a soybean expression vector such as pKR457. Further sub-cloning into other vectors as described in Example 6 or Example 8 would yield vectors suitable for expression and co-expression of the delta-8 desaturase in soybean.
- elongases in addition to the elongase from Mortierella alpina, other elongases can be cloned into the soybean expression vectors such as those described in Example 6 and Example 8.
- elongases with specificity for linoleic acid or alpha-linolenic acid such as that from lsochrysis galhana (WO 2002/077213) can be used.
- a suitable elongase from an organism other than Mortierella alpina can be cloned using methods similar to, but limited not to, the methods described in Example 2 and Example 3.
- PCR primers designed to introduce Not ⁇ sites at the 5' and 3' ends of the elongase can be used to amplify the gene.
- Soybean embryogenic suspension cultures (cv. Jack) can be maintained in 35 ml_ liquid medium SB 196 (infra) on a rotary shaker, 150 rpm, 26 ° C with cool white fluorescent lights on 16:8 hr day/night photoperiod at light intensity of 60-85 ⁇ E/m2/s. Cultures are subcultured every 7 days to two weeks by inoculating approximately 35 mg of tissue into 35 ml_ of fresh liquid SB196 (the preferred subculture interval is every 7 days).
- Soybean embryogenic suspension cultures can be transformed with the plasmids and DNA fragments described earlier by the method of particle gun bombardment (Klein et al., Nature, 327:70 (1987)) using a DuPont Biolistic PDS1000/HE instrument (helium retrofit) for all transformations.
- Soybean Embrvogenic Suspension Culture Initiation Soybean cultures are initiated twice each month with 5-7 days between each initiation. Pods with immature seeds from available soybean plants 45-55 days after planting are picked, removed from their shells and placed into a sterilized magenta box. The soybean seeds are sterilized by shaking them for 15 min in a 5% Clorox solution with 1 drop of ivory soap (i.e., 95 ml_ of autoclaved distilled water plus 5 ml_ Clorox and 1 drop of soap, mixed well). Seeds are rinsed using 2 1 -liter bottles of sterile distilled water and those less than 4 mm were placed on individual microscope slides.
- the small end of the seed is cut and the cotyledons pressed out of the seed coat. Cotyledons are transferred to plates containing SB1 medium (25- 30 cotyledons per plate). Plates are wrapped with fiber tape and stored for 8 weeks. After this time secondary embryos are cut and placed into SB196 liquid media for 7 days.
- Either an intact plasmid or a DNA plasmid fragment containing the genes of interest and the selectable marker gene can be used for bombardment. Fragments from plasmids such pKR274 and pKR685 or pKR681 and/or other expression plasmids can be obtained by gel isolation of digested plasmids. In each case, 100 ⁇ g of plasmid DNA can be used in 0.5 ml_ of the specific enzyme mix described below.
- Plasmids could be digested with Asc ⁇ (100 units) in NEBuffer 4 (20 mM Tris-acetate, 10 mM magnesium acetate, 50 mM potassium acetate, 1 mM dithiothreitol, pH 7.9), 100 ⁇ g/mL BSA, and 5 mM beta-mercaptoethanol at 37 0 C for 1.5 hr.
- the resulting DNA fragments could be separated by gel electrophoresis on 1% SeaPIaque GTG agarose (BioWhitaker Molecular Applications) and the DNA fragments containing EPA biosynthetic genes could be cut from the agarose gel.
- DNA can be purified from the agarose using the GELase digesting enzyme following the manufacturer's protocol. Alternatively, whole plasmids or a combination of whole plasmid with fragment could be used.
- a 50 ⁇ l aliquot of sterile distilled water containing 3 mg of gold particles can be added to 5 ⁇ l of a 1 ⁇ g/ ⁇ l DNA solution (either intact plasmid or DNA fragment prepared as described above), 50 ⁇ l 2.5M CaCI 2 and 20 ⁇ l of 0.1 M spermidine. The mixture is shaken 3 min on level 3 of a vortex shaker and spun for 10 sec in a bench microfuge. After a wash with 400 ⁇ l 100% ethanol, the pellet is suspended by sonication in 40 ⁇ l of 100% ethanol. Five ⁇ l of DNA suspension is dispensed to each flying disk of the Biolistic PDS1000/HE instrument disk. Each 5 ⁇ l aliquot contained approximately 0.375 mg gold particles per bombardment (i.e., per disk).
- Tissue Preparation and Bombardment with DNA Approximately 150-200 mg of 7 day old embryonic suspension cultures are placed in an empty, sterile 60 x 15 mm petri dish and the dish is covered with plastic mesh. Tissue is bombarded 1 or 2 shots per plate with membrane rupture pressure set at 1100 PSI and the chamber is evacuated to a vacuum of 27-28 inches of mercury. Tissue is placed approximately 3.5 inches from the retaining /stopping screen.
- Transformed embryos are selected either using hygromycin (when the hygromycin phosphotransferase, HPT, gene was used as the selectable marker) or chlorsulfuron (when the acetolactate synthase, ALS, gene was used as the selectable marker).
- hygromycin when the hygromycin phosphotransferase, HPT, gene was used as the selectable marker
- chlorsulfuron when the acetolactate synthase, ALS, gene was used as the selectable marker.
- the tissue is placed into fresh SB196 media and cultured as described above.
- the SB196 is exchanged with fresh SB196 containing either a selection agent of 30 mg/L hygromycin or a selection agent of 100 ng/mL chlorsulfuron.
- the selection media is refreshed weekly.
- Embryo Maturation Embryos can be cultured for 4-6 weeks at 26 ° C in SB196 under cool white fluorescent (Phillips cool white Econowatt F40/CW/RS/EW) and Agro (Phillips F40 Agro) bulbs (40 watt) on a 16:8 hr photoperiod with light intensity of 90-120 ⁇ E/m 2 s. After this time embryo clusters are removed to a solid agar media, SB166, for 1-2 weeks. Clusters are then subcultured to medium SB103 for 3 weeks. During this period, individual embryos can be removed from the clusters and screened for alterations in their fatty acid compositions as described in Example 11.
- any detectable phenotype resulting from the expression of the genes of interest, could be screened at this stage. This would include (but not be limited to) alterations in: fatty acid profile, protein profile and content, carbohydrate content, growth rate, viability, or the ability to develop normally into a soybean plant.
- Desiccation and Germination Matured individual embryos can be desiccated by placing them into an empty, small petri dish (35 x 10 mm) for approximately 4-7 days. The plates are sealed with fiber tape (creating a small humidity chamber). Desiccated embryos can be planted into SB71-4 medium where they are left to germinate under the same culture conditions described above.
- Germinated plantlets are removed from germination medium and rinsed thoroughly with water and then planted in Redi-Earth in 24-cell pack trays, covered with clear plastic domes. After 2 weeks the dome is removed and plants hardened off for a further week. If plantlets look hardy they are transplanted to 10" pots of Redi-Earth with up to 3 plantlets per pot. After 10 to 16 weeks, mature seeds can be harvested, chipped and analyzed for fatty acids as described above.
- MS salts (Catalog #11117-066, Gibco/ BRL) 1 mL B5 vitamins 1000X stock
- 2,4-D stock obtained premade from Phytotech, Catalog #D 295; concentration is 1 mg/mL B5 Vitamins Stock (per 100 ml_; store aliquots at -20 ° C) 1O g myo-inositol 100 mg nicotinic acid 100 mg pyridoxine HCI 1 g thiamine
- somatic embryos cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26 °C on an appropriate agar medium for 6-10 weeks. Somatic embryos, which produce secondary embryos, are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.
- Soybean embryogenic suspension cultures can be maintained in 35 ml_ liquid media on a rotary shaker, 150 rpm, at 26 0 C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 ml_ of liquid medium.
- Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. Nature (London) 327:70-73 (1987); U.S. 4,945,050).
- a DuPont Biolistic PDS1000/HE instrument helium retrofit
- a selectable marker gene which can be used to facilitate soybean transformation is a recombinant DNA construct composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. Nature 373:810-812 (1985)), the hygromycin phosphotransferase gene from plasmid pJR225 (from £. coli; Gritz et al. Gene
- the seed expression cassette comprising the phaseolin 5 1 region, the fragment encoding the instant polypeptide and the phaseolin 3 1 region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.
- Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette.
- approximately 5-10 plates of tissue are normally bombarded.
- Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury.
- the tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.
- the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly.
- green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.
- the amino acid sequence of the synthetic codon-optimized D8S-3 gene in pDMW261 was corrected according to the amino acid sequence of the functional Euglena delta-8 desaturase (SEQ ID NOs: 1 and 2).
- pDMW261 as a template and oligonucleotides ODMW404 (SEQ ID NO:94) and D8-13R (SEQ ID NO:36)
- the DNA fragment encoding the synthetic D8S-3 desaturase gene was amplified.
- the resulting PCR fragment was purified with Bio101's Geneclean kit and subsequently digested with Kpr?1 and Noft (primer ODMW404 introduced a Kpn ⁇ site while primer D8-13R introduced a Not ⁇ site).
- the KpnMNot ⁇ fragment (SEQ ID NO:95) was cloned into KpnVNoft digested pKUNFmKF2 ( Figure 5D; SEQ ID NO:116) to produce pDMW277 ( Figure 6A).
- the primers introduced into the PCR fragment a Nco1 site and BgIII site at its 5' and 3' ends, respectively.
- the 318 bp PCR product was purified with Bio101's GeneClean kit and subsequently digested with Nco1 and BgIII.
- the first reaction in a final series of site-directed mutagenesis reactions was then performed on pDMW287.
- the first set of primers, YL525 (SEQ ID NO:98) and YL526 (SEQ ID NO:99) was designed to correct amino acid from F to S (position #50) of the synthetic D8S-3 gene in pDMW287.
- the plasmid resulting from this mutagenesis reaction then became the template for the next site-directed mutagenesis reaction with YL527 (SEQ ID NO:100) and YL528 (SEQ ID NO:101) as primers.
- These primers were designed to correct the amino acid from F to S (position #67) of the D8S-3 gene and resulted in creation of plasmid pDMW287/YL527.
- the product (i.e., pDMW287/Y529) of this mutagenesis reaction was used as the template in the following reaction using primers YL531 (SEQ ID NO:104) and YL532 (SEQ ID NO:105) to correct the amino acid from P to L (position #213).
- the product of this reaction was called pDMW287/YL529-31.
- the method used to synthesize the codon-optimized delta-9 elongase gene was the same as that used for synthesis of the delta-8 desaturase gene (Example 1).
- Eight pairs of oligonucleotides were designed to extend the entire length of the codon-optimized coding region of the /.
- galbana delta-9 elongase gene e.g., IL3-1A, IL3-1 B, IL3-2A, 1L3-2B, IL3-3A, IL3-3B, IL3-4A, IL3-4B, IL3-5A, IL3-5B, IL3- 6A, IL3-6B, IL3-7A, IL3-7B, IL3-8A, IL3-8B, corresponding to SEQ ID NOs:121-136).
- Each pair of sense (A) and anti-sense (B) oligonucleotides were complementary, with the exception of a 4 bp overhang at each 5'-end.
- primers IL3-1 F, IL3-4R, IL3-5F and IL3-8R also introduced Ncol, Pstl, Pstl and Not1 restriction sites, respectively, for subsequent subcloning.
- Each oligonucleotide (100 ng) was phosphorylated at 37 °C for 1 hr in a volume of 20 ⁇ l containing 50 mM Tris-HCI (pH 7.5), 10 mM MgCl2, 10 mM DTT,
- IL3-1A SEQ ID NO:121
- IL3-1 B SEQ ID NO:122
- IL3-2A (SEQ ID NO:123) was annealed to IL3-2B (SEQ ID NO:124) to produce the double-stranded product "IL3-2AB", etc.
- Two separate pools of annealed, double-stranded oligonucleotides were then ligated together, as shown below: Pool 1 (comprising IL3-1AB, IL3-2AB, IL3-3AB and IL3-4AB); and, Pool 2 (comprising IL3-5AB, IL3-6AB, IL3-7AB and IL3-8AB).
- Each pool of annealed oligonucleotides was mixed in a volume of 20 ⁇ l with 10 U of
- ligated "Pool 2" mixture i.e. IL3-5AB, IL3-6AB, IL3-7AB and IL3- 8AB
- oligonucleotides IL3-5F and IL3-8R SEQ ID NOs: 139 and 140
- the second portion of the codon-optimized delta-9 elongase gene was amplified similarly by PCR and cloned into the pGEM-T-easy vector to generate pT9(5-8).
- Plasmid DNA was purified and digested with the appropriate restriction endonucleases to liberate the 417 bp Ncol/Pstl fragment of pT9(1-4) (SEQ ID NO: 141) and the 377 bp
- Strain Y2031 was generated by integration of the TEF::Y. ⁇ 12::Pex20 chimeric gene of plasmid pKUNT2 (Figure 7C) into the Ura3 gene locus of Yarrowia lipolytica ATCC #20362, to thereby generate the Ura-genotype of strain Y2031.
- plasmid pKUNT2 contained the following components:
- Plasmid pKUNT2 (SEQ ID NO:145)
- the pKUNT2 plasmid was digested with Ascl/Sphl, and then used for transformation of wild type Y. lipolytica ATCC #20362 according to the General Methods.
- the transformant cells were plated onto 5-fluoroorotic acid ("FOA"; also 5-fluorouracil-6-carboxylic acid monohydrate) selection media plates and maintained at 30 ° C for 2 to 3 days.
- FOA 5-fluoroorotic acid
- FOA selection media comprised: 0.17% yeast nitrogen base (DIFCO Laboratories, Detroit, Ml) without ammonium sulfate or amino acids, 2% glucose, 0.1% proline, 75 mg/L uracil, 75 mg/L uridine, 900 mg/L FOA (Zymo Research Corp., Orange, CA) and 20 g/L agar.
- the FOA resistant colonies were picked and streaked onto MM and MMU selection plates. The colonies that could grow on MMU plates but not on MM plates were selected as Ura- strains. Single colonies (5) of Ura- strains were then inoculated into liquid MMU at 30 C and shaken at 250 rpm/min for 2 days.
- the cells were collected by centrifugation, lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC. GC analyses showed that there were about 45% LA in two Ura - strains (strains #2 and #3), compared to about 20% LA in the wild type ATCC #20362. Transformant strain #2 was designated as strain "Y2031 ". Expression Of The Codon-Optimized Delta-9 Elonqase Gene In Y. lipolvtica
- Construct pDMW237 (comprising the chimeric FBAIN::lgD9e::Pex20 gene) was transformed into Yarrowia lipolytica strain Y2031, as described in the General Methods. Three transformants of Y2031 with pDMW237 were grown individually in MM media for two days. The cells were collected by centrifugation, lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC.
- the GC results showed that there were about 7.1%, 7.3% and 7.4% EDA produced in these transformants with pDMW237. These data demonstrated that the synthetic lgD9e could convert the C18:2 to EDA.
- the "percent (%) substrate conversion” or “conversion efficiency" of the codon-optimized gene was determined to be about 13%, wherein the conversion efficiency was calculated according to the following formula: ([product]/[substrate+product])*100, where 'product' includes the immediate product and all products in the pathway derived from it. This term refers to the efficiency by which the particular enzyme can convert substrate to product.
- the present Example describes DGLA biosynthesis and accumulation in Yarrowia lipolytica that was transformed to express the delta-9 elongase/ delta-8 desaturase pathway.
- this required co-synthesis of the synthetic codon- optimized delta-9 elongase (SEQ ID NO:118; Example 15) and the synthetic codon- optimized delta-8 desaturase (SEQ ID NO: 112; Example 14).
- Plasmid pDMW297 contained the following components: Table 8 Description of Plasmid pDMW297(SEQ ID NQ: 148)
- the pDMW297 plasmid was then used for transformation of strain Y2031
- Example 15 according to the General Methods.
- the transformant cells were plated onto MM selection media plates and maintained at 30 ° C for 2 to 3 days. A total of 8 transformants grown on the MM plates were picked and re-streaked onto fresh MM plates. Once grown, these strains were individually inoculated into liquid MM at 30 ° C and shaken at 250 rpm/min for 2 days. The cells were collected by centrifugation, lipids were extracted, and fatty acid methyl esters were prepared by trans-esterification, and subsequently analyzed with a Hewlett-Packard 6890 GC. GC analyses showed that DGLA was produced in all of the transformants analyzed.
- strain Y0489 One strain produced about 3.2%, 4 strains produced 4.3-4.5%, two strains produced 5.5-5.8% and one strain produced 6.4% DGLA (designated herein as strain "Y0489").
- the "percent (%) substrate conversion" of the codon-optimized D8SF gene in strain Y0489 was determined to be 75% (using the formula of
- Example 15 It will be obvious to one of skill in the art that other chimeric genes could be co-expressed with the D8SF and lgD9e genes in engineered Yarrowia to enable production of various other PUFAs.
- a delta-15 desaturase to enable production of ETA (2) a delta-5 desaturase to enable production of ARA; (3) a delta-17 desaturase to enable production of ETA; (4) a delta-5 desaturase and a delta-17 desaturase to enable production of EPA; (6) a delta-5 desaturase, a delta-17 desaturase and a C- 20/22 elongase to enable production of DPA; or (7) a delta-5 desaturase, a delta-17 desaturase, a C2 0 / 22 elongase and a delta-4 desaturase
- Plasmid pKR680 was digested with Ss/VVI and the fragment containing Eg5 (SEQ ID NO:1) was cloned into the Ss/WI site of pKR607 to give pKR682.
- the delta-8 desaturase Eg5; SEQ ID NO:1
- the lsochrysis galbana elongase behind strong, seed-specific promoters A map of pKR682 is shown in Figure 8A.
- soybean expression vector containing the Euglena gracilis delta-8 desaturase, the lsochrysis galbana delta-9 elongase and the Mortierella alpina delta-5 desaturase (all under control of strong seed specific promoters) was constructed in the following way.
- a sequence of DNA (SEQ ID NO: 151) was effectively added into the Sma ⁇ site of vector pKR287 (WO 2004/071467 A2) to produce pKR767.
- a Sbfl restriction site was added to the 3' end of the leg1A transcription terminator of the Gyi/Mad5/legA2 cassette.
- the Asc ⁇ fragment of pKR682 was cloned into the Asc ⁇ site of pKR277 (WO 2004/071467 A2) to produce pKR769.
- the Gy1/Mad5/legA2 cassette was released from pKR767 by digestion with
- the Kti3 promoter: Fm ⁇ 15 desaturase ORF:Kti3 terminator cassette was released from plasmid pKR578 (WO 2005/047479) by digestion with Ss/WI and was cloned into the Bs/WI site of plasmid pKR226 (WO 2004/071467 A2), containing the ALS gene for selection, the T7prom/hpt/T7term cassette and the bacterial on region, to produce pKR667.
- Plasmid pKR271 was digested with Pst ⁇ and the fragment containing the Saprolegnia diclina delta-17 desaturase was cloned into the Sbfl site of pKR667 to produce pKR669. In this way, the delta-15 desaturase could be co-expressed with the Saprolegnia diclina delta-17 desaturase behind strong, seed-specific promoters.
- a map of pKR669 is shown in Figure 8C.
- somatic soybean embryos While in the globular embryo state in liquid culture, somatic soybean embryos contain very low amounts of triacylglycerol or storage proteins typical of maturing, zygotic soybean embryos. At this developmental stage, the ratio of total triacylglyceride to total polar lipid (phospholipids and glycolipid) is about 1 :4, as is typical of zygotic soybean embryos at the developmental stage from which the somatic embryo culture was initiated. At the globular stage as well, the mRNAs for the prominent seed proteins, ⁇ '-subunit of ⁇ -conglycinin, kunitz trypsin inhibitor 3, and seed lectin are essentially absent.
- Transgenic somatic soybean embryos containing the constructs described above were analyzed in a similar way.
- fatty acid methyl esters were prepared from single, matured, somatic soy embryos by transesterification. Embryos were placed in a vial containing 50 ⁇ l_ of trimethylsulfonium hydroxide (TMSH) and 0.5 ml_ of hexane and incubated for 30 min at room temperature while shaking.
- Fatty acid methyl esters (5 ⁇ l_ injected from hexane layer) are separated and quantified using a Hewlett-Packard 6890 Gas Chromatograph fitted with an Omegawax 320 fused silica capillary column (Catalog #24152, Supelco Inc.).
- the oven temperature was programmed to hold at 220 0 C for 2.7 min, increase to 240 0 C at 20 °C/min and then hold for an additional 2.3 min.
- Carrier gas was supplied by a Whatman hydrogen generator. Retention times were compared to those for methyl esters of standards commercially available (Catalog #U-99-A, Nu-Chek Prep, Inc.). Routinely, 6-10 embryos per event were analyzed by GC, using the methodology described above.
- embryo fatty acid profiles for ⁇ 6 lines containing pKR681 are shown in Table 9.
- the best line (i.e., 1618-1-1-1) had embryos with an average DGLA content of 8.9% and an average ETA content of 3.1%.
- the best elongase line (i.e., 1618-4-1-1) had embryos with an average EDA content of 10.6% and an average EtrA content of 6.5%.
- Calculated % elongation, % desaturation and elongation and desaturation ratios are shown in Table 10.
- the delta-8 desaturase converts an average of 76.3% of the elongated C20 fatty acids to product with the best embryo converting 82.1% to product.
- the delta-8 desaturase appears to utilize EDA and EtrA equally well as the ratio of their respective % desaturations is around 1.0.
- the Mortiella alpina elongase converts an average of 23% of the C18 fatty axcids to product with the best embryo converting 30.2% to product.
- the elongase appears to have a slight preference for ALA as the ratio of their respective % elongations is around 0.6. Expression of only the elongase in these lines likely resulted from fragmentation of the construct during the transformation procedure or due to positional insertion effects differentially affecting expression of the delta-8.
- the C18 % Elongation (C18 % Elong) in Table 10 was calculated by dividing the sum of the wt.% for EDA, DGLA, EtrA and ETA (Table 9) by the sum of the wt.% for LA, ALA, EDA, DGLA, EtrA and ETA (Table 9) and multiplying by 100 to express as a %.
- the C20 % ⁇ 8 desaturation (C20 % ⁇ 8 desat. Table 10) was calculated by dividing the sum of the wt.% for DGLA and ETA (Table 9) by the sum of the wt.% for EDA, DGLA, EtrA and ETA (Table 9) and multiplying by 100 to express as a %.
- the individual elongations (LA % Elong or ALA % Elong) or ⁇ 8 desaturations (EDA % ⁇ 8 desat or EtrA % ⁇ 8 desat) shown in Table 10 were calculated in a similar way but only using either the ⁇ -6 substrates/products or the ⁇ -3 substrates/products for each.
- the Ratio elongation for LA and ALA was obtained by dividing the LA % Elongation by the ALA % elongation.
- the Ratio delta-8 desaturation was obtained by dividing the EDA % delta-8 desaturation by the EtrA % delta-8 desaturation.
- Embryo fatty acid profiles for 9 lines containing pKR682 are shown in Table 11. Calculated % elongation, % desaturation and elongation and desaturation ratios are shown in Table 12. The best line (1619-6-7) had embryos with an average
- DGLA content 21.8% and an average ETA content of 4.1 %.
- the delta-8 desaturase converts an average of 91.6% of the elongated C20 fatty acids to product and, in the best embryo (1619-6-7-1), 95.1% of the elongated fatty acids are converted to product.
- the delta-8 desaturase appears to utilize EDA and EtrA equally well with the ratio of their respective % desaturations being around 1.0 (Table 12). In these lines, the average % conversion of C18 fatty acids to C20 fatty acids ranges from 40.0% to 49.5%.
- the C18 % Elongation (C18 % Elong) in Table 12 was calculated by dividing the sum of the wt.% for EDA, DGLA, EtrA and ETA (Table 11) by the sum of the wt.% for LA, ALA, EDA, DGLA, EtrA and ETA (Table 11) and multiplying by 100 to express as a %.
- Table 12 was calculated by dividing the sum of the wt.% for DGLA and ETA (Table 11) by the sum of the wt.% for EDA, DGLA, EtrA and ETA (Table 11) and multiplying by 100 to express as a %.
- the individual elongations (LA % Elong or ALA % Elong) or ⁇ 8 desaturations (EDA % ⁇ 8 desat or EtrA % ⁇ 8 desat) shown in Table 12 were calculated in a similar way but only using either the ⁇ -6 substrates/products or the ⁇ -3 substrates/products for each.
- the Ratio elongation for LA and ALA was obtained by dividing the LA % Elongation by the ALA % elongation.
- the Ratio delta-8 desaturation was obtained by dividing the EDA % delta-8 desaturation by the EtrA % delta-8 desaturation.
- Plasmid pKR786 and pKR669 were digested with Asc ⁇ and the DNA fragments containing ALS selection and EPA biosynthetic genes were transformed into soy as described previously. Fatty acids from ten embryos for each line obtained containg pKR786 and pKR669 were analyzed by GC as described.
- Fatty acids in Table 13 and Table 14 are defined as X:Y where X is the fatty acid chain length and Y is the number of double bonds.
- Fatty acids listed as "others” include: 18:2(6,9), 20:0, 20:1(11), 20:2(8,11) and 20:3 (5,11 ,14). Each of these fatty acids is present at a relative abundance of less than 2% of the total fatty acids. In all of the top lines, GLA is not present or is present at levels less than 0.2%.
- Fatty acid compositions listed in Table 14 are expressed as wt.%.
- EtrA Eicosatrienoic acid
- ETA Eicosa-tetraenoic acid
- EPA Eicosa-pentaenoic acid
- DPA Docosa-pentaenoic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0512481-6A BRPI0512481A (en) | 2004-06-25 | 2005-06-24 | isolated polynucleotide, polypeptide, recombinant construct, cell, transformed yarrowia sp.transformed, methods for transforming a cell, producing a transformed plant, producing yeast, producing polyunsaturated fatty acids and producing at least one polyunsaturated fatty acid, seeds, oils, oilseed plants and food or feed |
AU2005267202A AU2005267202B2 (en) | 2004-06-25 | 2005-06-24 | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
CA2568624A CA2568624C (en) | 2004-06-25 | 2005-06-24 | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
EP05768249A EP1758991B1 (en) | 2004-06-25 | 2005-06-24 | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58304104P | 2004-06-25 | 2004-06-25 | |
US60/583,041 | 2004-06-25 | ||
US62481204P | 2004-11-04 | 2004-11-04 | |
US60/624,812 | 2004-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006012325A1 true WO2006012325A1 (en) | 2006-02-02 |
Family
ID=34980122
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/022547 WO2006012325A1 (en) | 2004-06-25 | 2005-06-24 | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
PCT/US2005/022548 WO2006012326A1 (en) | 2004-06-25 | 2005-06-24 | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/022548 WO2006012326A1 (en) | 2004-06-25 | 2005-06-24 | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
Country Status (6)
Country | Link |
---|---|
US (3) | US7256033B2 (en) |
EP (1) | EP1758991B1 (en) |
AU (1) | AU2005267202B2 (en) |
BR (1) | BRPI0512481A (en) |
CA (1) | CA2568624C (en) |
WO (2) | WO2006012325A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007061742A1 (en) | 2005-11-23 | 2007-05-31 | E. I. Du Pont De Nemours And Company | Delta-9 elongases and their use in making polyunsaturated fatty acids |
WO2007127381A2 (en) | 2006-04-28 | 2007-11-08 | E. I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
WO2007093776A3 (en) * | 2006-02-16 | 2007-12-06 | Basf Plant Science Gmbh | Nucleic acid |
WO2008073275A2 (en) * | 2006-12-07 | 2008-06-19 | E. I. Du Pont De Nemours And Company | Mutant delta-8 desaturase genes engineered by targeted mutagensis and their use in making polyunsaturated fatty acids |
WO2008073271A1 (en) * | 2006-12-07 | 2008-06-19 | E. I. Du Pont De Nemours And Company | Mutant delta8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids |
WO2008124806A2 (en) | 2007-04-10 | 2008-10-16 | E. I. Du Pont De Nemours And Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
WO2008128241A1 (en) | 2007-04-16 | 2008-10-23 | E. I. Du Pont De Nemours And Company | Delta 9 elongases and their use in making polyunsaturated fatty acids |
WO2008137532A1 (en) | 2007-05-03 | 2008-11-13 | E. I. Du Pont De Nemours And Company | Delta-5 desaturases and their use in making polyunsaturated fatty acids |
WO2008063340A3 (en) * | 2006-10-23 | 2008-11-20 | Du Pont | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
US7678560B2 (en) | 2006-05-17 | 2010-03-16 | E.I. Du Pont De Nemours And Company | Δ 5 desaturase and its use in making polyunsaturated fatty acids |
US7695950B2 (en) | 2006-05-17 | 2010-04-13 | E. I. Du Pont De Nemours And Company | Δ5 desaturase and its use in making polyunsaturated fatty acids |
US8013215B2 (en) | 2007-02-12 | 2011-09-06 | E.I. Du Pont De Nemours And Company | Production of arachidonic acid in oilseed plants |
WO2012001144A1 (en) | 2010-07-01 | 2012-01-05 | Institut National De La Recherche Agronomique | Optimization of lipid synthesis and accretion |
WO2012027698A1 (en) | 2010-08-26 | 2012-03-01 | E.I. Du Pont De Nemours And Company | Mutant hpgg motif and hdash motif delta-5 desaturases and their use in making polyunsaturated fatty acids |
US8153859B2 (en) | 2008-05-23 | 2012-04-10 | E.I. Du Pont De Nemours And Company | DGAT genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
US8597931B2 (en) | 2008-07-11 | 2013-12-03 | Institut National De La Recherche Agronomique (Inra) | Mutant yeast strains capable of accumulating a large quantity of lipids |
US8828690B2 (en) | 2007-04-03 | 2014-09-09 | E I Du Pont De Nemours And Company | Multizymes comprising delta-9 elongase and delta-8 desaturase and their use in making polyunsaturated fatty acids |
WO2015189352A1 (en) | 2014-06-11 | 2015-12-17 | Institut National De La Recherche Agronomique | Improved lipid accumulation in yarrowia lipolytica strains by overexpression of hexokinase and new strains thereof |
US10760089B2 (en) | 2014-11-14 | 2020-09-01 | Basf Plant Science Company Gmbh | Materials and methods for increasing the tocopherol content in seed oil |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6825017B1 (en) * | 1998-12-07 | 2004-11-30 | Washington State University Research Foundation | Desaturases and methods of using them for synthesis of polyunsaturated fatty acids |
US8791327B2 (en) | 1998-12-07 | 2014-07-29 | Washington State University Research Foundation | Desaturases and methods of using them for synthesis of polyunsaturated fatty acids |
ATE322916T1 (en) * | 2002-09-10 | 2006-04-15 | Scil Technology Gmbh | METAL IMPLANT COATED WITH AN OSTEOINDUCTIVE PROTEIN UNDER REDUCED OXYGEN CONCENTRATION |
BR0317304A (en) * | 2002-12-19 | 2005-11-08 | Univ Bristol | Process for the production of compounds, isolated nucleic acid sequence, amino acid sequence, gene construct, vector, and, organism |
US7834250B2 (en) | 2004-04-22 | 2010-11-16 | Commonwealth Scientific And Industrial Research Organisation | Synthesis of long-chain polyunsaturated fatty acids by recombinant cells |
CN102559364B (en) | 2004-04-22 | 2016-08-17 | 联邦科学技术研究组织 | Use recombinant cell synthesis of long-chain polyunsaturated fatty acids |
US7588931B2 (en) * | 2004-11-04 | 2009-09-15 | E. I. Du Pont De Nemours And Company | High arachidonic acid producing strains of Yarrowia lipolytica |
US20060281071A1 (en) * | 2005-06-08 | 2006-12-14 | Ntambi James M | Stearoyl-CoA desaturase assay |
CA2661697A1 (en) | 2006-08-29 | 2008-03-06 | Commonwealth Scientific And Industrial Research Organisation | Synthesis of fatty acids |
WO2009046231A1 (en) | 2007-10-03 | 2009-04-09 | E. I. Du Pont De Nemours And Company | Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production |
CN101951755A (en) * | 2007-12-21 | 2011-01-19 | 加拿大国家研究委员会 | Diacylglycerol acyltransferase 2 genes and proteins encoded thereby from algae |
EP2358882B1 (en) | 2008-11-18 | 2017-07-26 | Commonwealth Scientific and Industrial Research Organisation | Enzymes and methods for producing omega-3 fatty acids |
BRPI0917722A2 (en) | 2008-12-18 | 2017-05-30 | Du Pont | transgenic organism and method for manipulating malonate content in a transgenic organism |
BRPI1009649A2 (en) | 2009-06-16 | 2016-03-15 | Du Pont | recombinant yarrowia sp host cell, method for making a microbial oil and recombinant host cell for producing an oil |
WO2010147900A1 (en) | 2009-06-16 | 2010-12-23 | E. I. Du Pont De Nemours And Company | IMPROVEMENT OF LONG CHAIN OMEGA-3 AND OMEGA-6 POLYUNSATURATED FATTY ACID BIOSYNTHESIS BY EXPRESSION OF ACYL-CoA LYSOPHOSPHOLIPID ACYLTRANSFERASES |
WO2010147907A1 (en) | 2009-06-16 | 2010-12-23 | E. I. Du Pont De Nemours And Company | High eicosapentaenoic acid oils from improved optimized strains of yarrowia lipolytica |
WO2011034199A1 (en) | 2009-09-18 | 2011-03-24 | サントリーホールディングス株式会社 | Glycerol-3-phosphate acyl transferase |
EP2516638A1 (en) | 2009-12-24 | 2012-10-31 | E.I. Du Pont De Nemours And Company | Plant membrane bound o-acyl transferase (mboat) family protein sequences and their uses for altering fatty acid compositions |
US20110178105A1 (en) | 2010-01-15 | 2011-07-21 | E.I. Du Pont De Nemours And Company | Clinical benefits of eicosapentaenoic acid in humans |
CN103282474A (en) | 2010-04-22 | 2013-09-04 | 纳幕尔杜邦公司 | Method for obtaining polyunsaturated fatty acid-ontaining compositions from microbial biomass |
US8915661B2 (en) | 2010-04-23 | 2014-12-23 | Hewlett-Packard Development Company, L.P. | Media drive restraint |
US20120040076A1 (en) | 2010-08-11 | 2012-02-16 | E. I. Du Pont De Nemours And Company | Aquaculture feed compositions |
WO2012021703A1 (en) | 2010-08-11 | 2012-02-16 | E. I. Du Pont De Nemours And Company | A sustainable aquaculture feeding strategy |
CA2805882A1 (en) | 2010-08-11 | 2012-02-16 | E. I. Dupont De Nemours And Company | Improved aquaculture meat products |
BR112013004356A2 (en) | 2010-08-26 | 2017-06-27 | Du Pont | isolated polynucleotide, mutant polypeptide, recombinant construct, transformed cell, method for producing a polyunsaturated fatty acid, microbial oil and recombinant microbial host cell. |
AU2011293180B2 (en) * | 2010-08-26 | 2017-03-02 | E. I. Du Pont De Nemours And Company | Recombinant microbial host cells for high eicosapentaenoic acid production |
KR20140000711A (en) | 2010-12-30 | 2014-01-03 | 이 아이 듀폰 디 네모아 앤드 캄파니 | Use of saccaromyces cerevisiae suc2 gene in yarrowia lipolytica for sucrose utilization |
US20130040340A1 (en) | 2011-02-07 | 2013-02-14 | E. I. Du Pont De Nemours And Company | Production of alcohol esters in situ using alcohols and fatty acids produced by microorganisms |
JP2014510166A (en) * | 2011-02-11 | 2014-04-24 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Purification of triglyceride oil from microbial sources using short path distillation |
US20120247066A1 (en) | 2011-04-01 | 2012-10-04 | Ice House America, Llc | Ice bagging apparatus and methods |
US8946460B2 (en) | 2012-06-15 | 2015-02-03 | Commonwealth Scientific And Industrial Research Organisation | Process for producing polyunsaturated fatty acids in an esterified form |
EP2935591B1 (en) | 2012-12-21 | 2017-07-05 | E. I. du Pont de Nemours and Company | Down-regulation of a polynucleotide encoding a sou2 sorbitol utilization protein to modify lipid production in microbial cells |
SG11201604871VA (en) | 2013-12-18 | 2016-07-28 | Commw Scient Ind Res Org | Lipid comprising long chain polyunsaturated fatty acids |
KR102527795B1 (en) | 2014-06-27 | 2023-05-02 | 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 | Lipid comprising docosapentaenoic acid |
MY190074A (en) * | 2018-01-09 | 2022-03-24 | Aimst Univ | A monovalent vaccine formulation and a method for preparation thereof |
CN110972946B (en) * | 2019-12-19 | 2022-04-01 | 美尚生态景观股份有限公司 | Subculture method of rabdosia amethystoides |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005277A2 (en) * | 1978-05-08 | 1979-11-14 | Cpc International Inc. | Process for the microbiological production of oil |
US5004863A (en) | 1986-12-03 | 1991-04-02 | Agracetus | Genetic engineering of cotton plants and lines |
WO1992017598A1 (en) | 1991-03-29 | 1992-10-15 | The Board Of Trustees Of The University Of Illinois | Production fo transgenic soybean plants |
US5416011A (en) | 1988-07-22 | 1995-05-16 | Monsanto Company | Method for soybean transformation and regeneration |
US5463174A (en) | 1986-05-29 | 1995-10-31 | Calgene Inc. | Transformation and foreign gene expression in Brassica species |
WO1998046764A1 (en) | 1997-04-11 | 1998-10-22 | Calgene Llc | Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants |
WO1998046763A1 (en) | 1997-04-11 | 1998-10-22 | Calgene Llc | Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
US5972664A (en) | 1997-04-11 | 1999-10-26 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
WO2000012720A2 (en) | 1998-09-02 | 2000-03-09 | Abbott Laboratories | Elongase genes and uses thereof |
US6051754A (en) | 1997-04-11 | 2000-04-18 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants |
US6075183A (en) | 1997-04-11 | 2000-06-13 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants |
WO2000034439A1 (en) * | 1998-12-07 | 2000-06-15 | Washington State University Research Foundation | Desaturases and methods of using them for synthesis of polyunsaturated fatty acids |
WO2000040705A2 (en) | 1999-01-08 | 2000-07-13 | Abbott Laboratories | Human desaturase gene and uses thereof |
WO2002031178A1 (en) * | 2000-10-12 | 2002-04-18 | Uab Research Foundation | An artificial gene and vectors for expressing high-yield recombinant ovine interferon-tau in pichia pastoris |
WO2002077213A2 (en) * | 2001-03-26 | 2002-10-03 | University Of Bristol | New elongase gene and production of δ9-polyunsaturated fatty acids |
WO2004057001A2 (en) * | 2002-12-19 | 2004-07-08 | University Of Bristol | Method for the production of polyunsaturated fatty acids |
WO2004071467A2 (en) | 2003-02-12 | 2004-08-26 | E. I. Du Pont De Nemours And Company | Production of very long chain polyunsaturated fatty acids in oilseed plants |
WO2004071178A2 (en) | 2003-02-12 | 2004-08-26 | E. I. Du Pont De Nemours And Company | Annexin and p34 promoters and use in expression of transgenic genes in plants |
WO2004101757A2 (en) | 2003-05-07 | 2004-11-25 | E.I. Dupont De Nemours And Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
WO2004101753A2 (en) | 2003-05-07 | 2004-11-25 | E.I. Dupont De Nemours And Company | Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts |
WO2005012316A2 (en) * | 2003-08-01 | 2005-02-10 | Basf Plant Science Gmbh | Method for the production of multiply-unsaturated fatty acids in transgenic organisms |
WO2005047485A2 (en) * | 2003-11-12 | 2005-05-26 | E.I. Dupont De Nemours And Company | Delta12 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous yeast |
WO2005083093A2 (en) * | 2004-02-27 | 2005-09-09 | Basf Plant Science Gmbh | Method for producing polyunsaturated fatty acids in transgenic plants |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057419A (en) | 1988-09-22 | 1991-10-15 | Rutgers University | Genetically engineered plasmid and organisms for the production of specialized oils |
ATE241007T1 (en) | 1990-03-16 | 2003-06-15 | Calgene Llc | DNAS CODING FOR PLANT DESATURASES AND THEIR APPLICATIONS |
DK0537178T4 (en) | 1990-05-25 | 2007-07-16 | Du Pont | Nucleotide sequence of soybean stearoyl ACP desaturase gene |
DE69233118T2 (en) | 1991-12-04 | 2004-04-15 | E.I. Du Pont De Nemours And Co., Wilmington | FATTY ACID DESATURASE GENES FROM PLANTS |
DK0668919T3 (en) | 1992-11-17 | 2003-09-15 | Du Pont | Genes for microsomal delta-12 fatty acid desaturases and related plant enzymes |
US6140486A (en) | 1997-06-04 | 2000-10-31 | Calgene Llc | Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants |
CA2330024C (en) | 1998-06-12 | 2012-01-24 | Calgene Llc | Polyunsaturated fatty acids in plants |
US6825017B1 (en) | 1998-12-07 | 2004-11-30 | Washington State University Research Foundation | Desaturases and methods of using them for synthesis of polyunsaturated fatty acids |
MXPA03000507A (en) | 2000-07-21 | 2003-10-06 | Du Pont | A CYTOCHROME P450 ENZYME ASSOCIATED WITH THE SYNTHESIS OF Dgr;12. |
DK1911837T3 (en) | 2000-09-28 | 2011-08-29 | Bioriginal Food & Science Corp | FAD5-2 fatty acid desaturase family member and uses thereof |
JP2002296554A (en) | 2001-03-30 | 2002-10-09 | Minebea Co Ltd | Faraday rotator |
CN1208545C (en) | 2001-07-24 | 2005-06-29 | 三洋电机株式会社 | Starling refrigerator |
EP1549133B1 (en) | 2002-05-22 | 2015-04-22 | Monsanto Technology LLC | Fatty acid desaturases from fungi |
NL1022683C1 (en) | 2003-02-14 | 2004-08-17 | Sluis Cigar Machinery B V V D | Manufacture of a culture medium useful for growing plants involves mixing a particulate base material with a binding agent, partly fluidizing the binding agent and cooling the mixture to bond the base material with the binding agent |
US7214491B2 (en) | 2003-05-07 | 2007-05-08 | E. I. Du Pont De Nemours And Company | Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts |
-
2005
- 2005-06-24 AU AU2005267202A patent/AU2005267202B2/en active Active
- 2005-06-24 WO PCT/US2005/022547 patent/WO2006012325A1/en active Application Filing
- 2005-06-24 US US11/166,993 patent/US7256033B2/en not_active Expired - Fee Related
- 2005-06-24 WO PCT/US2005/022548 patent/WO2006012326A1/en not_active Application Discontinuation
- 2005-06-24 US US11/166,003 patent/US7550651B2/en active Active
- 2005-06-24 CA CA2568624A patent/CA2568624C/en active Active
- 2005-06-24 BR BRPI0512481-6A patent/BRPI0512481A/en not_active IP Right Cessation
- 2005-06-24 EP EP05768249A patent/EP1758991B1/en not_active Revoked
-
2009
- 2009-04-29 US US12/431,813 patent/US20090264666A1/en not_active Abandoned
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005277A2 (en) * | 1978-05-08 | 1979-11-14 | Cpc International Inc. | Process for the microbiological production of oil |
US5463174A (en) | 1986-05-29 | 1995-10-31 | Calgene Inc. | Transformation and foreign gene expression in Brassica species |
US5004863A (en) | 1986-12-03 | 1991-04-02 | Agracetus | Genetic engineering of cotton plants and lines |
US5159135A (en) | 1986-12-03 | 1992-10-27 | Agracetus | Genetic engineering of cotton plants and lines |
US5004863B1 (en) | 1986-12-03 | 1992-12-08 | Agracetus | |
US5159135B1 (en) | 1986-12-03 | 2000-10-24 | Agracetus | Genetic engineering of cotton plants and lines |
US5004863B2 (en) | 1986-12-03 | 2000-10-17 | Agracetus | Genetic engineering of cotton plants and lines |
US5416011A (en) | 1988-07-22 | 1995-05-16 | Monsanto Company | Method for soybean transformation and regeneration |
US5569834A (en) | 1988-07-22 | 1996-10-29 | Monsanto Company | Method for soybean transformation and regeneration |
WO1992017598A1 (en) | 1991-03-29 | 1992-10-15 | The Board Of Trustees Of The University Of Illinois | Production fo transgenic soybean plants |
US6075183A (en) | 1997-04-11 | 2000-06-13 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants |
US6410288B1 (en) | 1997-04-11 | 2002-06-25 | Calgene, Inc. | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
US6051754A (en) | 1997-04-11 | 2000-04-18 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants |
US5968809A (en) | 1997-04-11 | 1999-10-19 | Abbot Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
US5972664A (en) | 1997-04-11 | 1999-10-26 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
WO1998046763A1 (en) | 1997-04-11 | 1998-10-22 | Calgene Llc | Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
US6136574A (en) | 1997-04-11 | 2000-10-24 | Abbott Laboratories | Methods and compositions for synthesis of long chain polyunsaturated fatty acids |
WO1998046764A1 (en) | 1997-04-11 | 1998-10-22 | Calgene Llc | Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants |
WO2000012720A2 (en) | 1998-09-02 | 2000-03-09 | Abbott Laboratories | Elongase genes and uses thereof |
WO2000034439A1 (en) * | 1998-12-07 | 2000-06-15 | Washington State University Research Foundation | Desaturases and methods of using them for synthesis of polyunsaturated fatty acids |
WO2000040705A2 (en) | 1999-01-08 | 2000-07-13 | Abbott Laboratories | Human desaturase gene and uses thereof |
WO2002031178A1 (en) * | 2000-10-12 | 2002-04-18 | Uab Research Foundation | An artificial gene and vectors for expressing high-yield recombinant ovine interferon-tau in pichia pastoris |
WO2002077213A2 (en) * | 2001-03-26 | 2002-10-03 | University Of Bristol | New elongase gene and production of δ9-polyunsaturated fatty acids |
WO2004057001A2 (en) * | 2002-12-19 | 2004-07-08 | University Of Bristol | Method for the production of polyunsaturated fatty acids |
WO2004071467A2 (en) | 2003-02-12 | 2004-08-26 | E. I. Du Pont De Nemours And Company | Production of very long chain polyunsaturated fatty acids in oilseed plants |
WO2004071178A2 (en) | 2003-02-12 | 2004-08-26 | E. I. Du Pont De Nemours And Company | Annexin and p34 promoters and use in expression of transgenic genes in plants |
WO2004101757A2 (en) | 2003-05-07 | 2004-11-25 | E.I. Dupont De Nemours And Company | Production of polyunsaturated fatty acids in oleaginous yeasts |
WO2004101753A2 (en) | 2003-05-07 | 2004-11-25 | E.I. Dupont De Nemours And Company | Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts |
WO2005012316A2 (en) * | 2003-08-01 | 2005-02-10 | Basf Plant Science Gmbh | Method for the production of multiply-unsaturated fatty acids in transgenic organisms |
WO2005047485A2 (en) * | 2003-11-12 | 2005-05-26 | E.I. Dupont De Nemours And Company | Delta12 desaturases suitable for altering levels of polyunsaturated fatty acids in oleaginous yeast |
WO2005083093A2 (en) * | 2004-02-27 | 2005-09-09 | Basf Plant Science Gmbh | Method for producing polyunsaturated fatty acids in transgenic plants |
Non-Patent Citations (29)
Title |
---|
"Plant Molecular Biology: A Laboratory Manual", 1997, SPRINGER |
BIRREN ET AL.: "Genome Analysis: Analyzing DNA", vol. 2, 1998, COLD SPRING HARBOR |
BIRREN ET AL.: "Genome Analysis: Detecting Genes", vol. 1, 1998, COLD SPRING HARBOR |
CHEN, D. C. ET AL., APPL. MICROBIOL BIOTECHNOL., vol. 48, no. 2, 1997, pages 232 - 235 |
CHENG ET AL., PLANT CELL REP., vol. 15, 1996, pages 653 - 657 |
CHOWRIRA, G.M. ET AL., MOL. BIOTECHNOL., vol. 3, 1995, pages 17 - 23 |
CHRISTOU ET AL., PLANT PHYSIOL., vol. 87, 1988, pages 671 - 674 |
CHRISTOU, P. ET AL., PROC. NAFL. ACAD. SCI. U.S.A., vol. 84, 1987, pages 3962 - 3966 |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; September 2002 (2002-09-01), LIN TAO ET AL: "High-frequency codon analysis and its application in codon analysis of tobacco.", XP002348320, Database accession no. PREV200300003812 * |
DATABASE EMBL [online] 21 September 2005 (2005-09-21), "Sequence 1 from Patent WO2005083093.", XP002348325, retrieved from EBI accession no. EM_PRO:CS160815 Database accession no. CS160815 * |
DATABASE EMBL [online] 23 February 2005 (2005-02-23), "Sequence 1 from Patent WO2005012316.", XP002348321, retrieved from EBI accession no. EM_PRO:CS020047 Database accession no. CS020047 * |
DATABASE EMBL [online] 29 July 2004 (2004-07-29), "Sequence 1 from Patent WO2004057001.", XP002348323, retrieved from EBI accession no. EM_PRO:CQ831420 Database accession no. CQ831420 * |
DATABASE EPO Proteins [online] 23 February 2005 (2005-02-23), "Sequence 2 from Patent WO2005012316.", XP002348322, retrieved from EBI accession no. EPOP:CS020048 Database accession no. CS020048 * |
DATABASE EPO Proteins [online] 29 July 2004 (2004-07-29), "Sequence 2 from Patent WO2004057001.", XP002348324, retrieved from EBI accession no. EPOP:CQ831421 Database accession no. CQ831421 * |
DATABASE UniProt [online] 1 May 2000 (2000-05-01), WALLIS J.G., BROWSE J.: "The Delta8-desaturase of Euglena gracilis: an alternate pathway for RT synthesis of 20-carbon polyunsaturated fatty acids", XP002348565, retrieved from EBI accession no. Q9SWQ9_EUGGR Database accession no. Q9SWQ9 * |
GRANT ET AL., PLANT CELL REP., vol. 15, 1995, pages 254 - 258 |
LING, K. ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 752 - 758 |
MALIGA: "Methods in Plant Molecular Biology", 1995, COLD SPRING HARBOR |
MCCABE, D.E., BIOLTECHNOLOGY, vol. 6, 1988, pages 923 |
MCKENTLY ET AL., PLANT CELL REP., vol. 14, 1995, pages 699 - 703 |
MELNIKOV ET AL., NUCLEIC ACIDS RESEARCH, vol. 27, no. 4, 15 February 1999 (1999-02-15), pages 1056 - 1062 |
NEWELL, C.A., MOL. BIOTECHNOL., vol. 16, 2000, pages 53 - 65 |
PATTERSON, H. B. W.: "Hydrogenation of Fats and Oils: Theory and Practice", 1994, THE AMERICAN OIL CHEMISTS' SOCIETY |
QI BAOXIU ET AL: "Production of very long chain polyunsaturated omega-3 and omega-6 fatty acids in plants", NATURE BIOTECHNOLOGY, vol. 22, no. 6, June 2004 (2004-06-01), pages 739 - 745, XP002348313, ISSN: 1087-0156 * |
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR |
TEPFLER, M.; CASSE-DELBART, F., MICROBIOL. SCI., vol. 4, 1987, pages 24 - 28 |
WALLIS J G ET AL: "The DELTA8-desaturase of Euglena gracilis: An alternate pathway for synthesis of 20-carbon polyunsaturated fatty acids", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, vol. 365, no. 2, 15 May 1999 (1999-05-15), pages 307 - 316, XP002291433, ISSN: 0003-9861 * |
WEISSBACH; WEISSBACH: "Methods for Plant Molecular Biology", 1988, ACADEMIC |
XIAMEN DAXUE XUEBAO (ZIRAN KEXUE BAN), vol. 41, no. 5, September 2002 (2002-09-01), pages 551 - 554, ISSN: 0438-0479 * |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645604B2 (en) | 2005-11-23 | 2010-01-12 | E.I. Du Pont De Nemours And Company | Delta-9 elongases and their use in making polyunsaturated fatty acids |
US8048653B2 (en) | 2005-11-23 | 2011-11-01 | E.I. Du Pont De Nemours And Company | Microbial oils produced in transformed host cells comprising delta-9 elongases |
WO2007061742A1 (en) | 2005-11-23 | 2007-05-31 | E. I. Du Pont De Nemours And Company | Delta-9 elongases and their use in making polyunsaturated fatty acids |
US8119861B2 (en) | 2006-02-16 | 2012-02-21 | Basf Plant Science Gmbh | Elongase and uses thereof |
WO2007093776A3 (en) * | 2006-02-16 | 2007-12-06 | Basf Plant Science Gmbh | Nucleic acid |
EP2380984A3 (en) * | 2006-02-16 | 2011-11-30 | BASF Plant Science GmbH | Nucleic acid |
EP2405012A1 (en) | 2006-04-28 | 2012-01-11 | E.I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
US8470571B2 (en) | 2006-04-28 | 2013-06-25 | E. I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
US7943823B2 (en) | 2006-04-28 | 2011-05-17 | E.I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
AU2007243286B2 (en) * | 2006-04-28 | 2011-12-08 | Corteva Agriscience Llc | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
US8058517B2 (en) | 2006-04-28 | 2011-11-15 | E.I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
WO2007127381A3 (en) * | 2006-04-28 | 2008-01-10 | Du Pont | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
WO2007127381A2 (en) | 2006-04-28 | 2007-11-08 | E. I. Du Pont De Nemours And Company | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
US8962917B2 (en) | 2006-05-17 | 2015-02-24 | E. I. Du Pont De Nemours And Company | Delta-5 desaturase and its use in making polyunsaturated fatty acids |
US7678560B2 (en) | 2006-05-17 | 2010-03-16 | E.I. Du Pont De Nemours And Company | Δ 5 desaturase and its use in making polyunsaturated fatty acids |
US7695950B2 (en) | 2006-05-17 | 2010-04-13 | E. I. Du Pont De Nemours And Company | Δ5 desaturase and its use in making polyunsaturated fatty acids |
US8049070B2 (en) | 2006-05-17 | 2011-11-01 | E.I. Du Pont De Nemours And Company | Delta-5 desaturase and its use in making polyunsaturated fatty acids |
US8859849B2 (en) | 2006-10-23 | 2014-10-14 | E. I. Du Pont De Nemours And Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
AU2007322223B2 (en) * | 2006-10-23 | 2012-12-13 | Corteva Agriscience Llc | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
US7863502B2 (en) | 2006-10-23 | 2011-01-04 | E.I. Dupont De Nemours And Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
EP2390339A1 (en) | 2006-10-23 | 2011-11-30 | E. I. du Pont de Nemours and Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
EP2390338A1 (en) | 2006-10-23 | 2011-11-30 | E. I. du Pont de Nemours and Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
WO2008063340A3 (en) * | 2006-10-23 | 2008-11-20 | Du Pont | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
US7709239B2 (en) | 2006-12-07 | 2010-05-04 | E.I. Du Pont De Nemours And Company | Mutant Δ8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids |
WO2008073275A3 (en) * | 2006-12-07 | 2008-08-07 | Du Pont | Mutant delta-8 desaturase genes engineered by targeted mutagensis and their use in making polyunsaturated fatty acids |
WO2008073275A2 (en) * | 2006-12-07 | 2008-06-19 | E. I. Du Pont De Nemours And Company | Mutant delta-8 desaturase genes engineered by targeted mutagensis and their use in making polyunsaturated fatty acids |
US8017838B2 (en) | 2006-12-07 | 2011-09-13 | E.I. Du Pont De Nemours And Company | Mutant delta-8 desaturase genes engineered by targeted mutagensis and their use in making polyunsaturated fatty acids |
WO2008073271A1 (en) * | 2006-12-07 | 2008-06-19 | E. I. Du Pont De Nemours And Company | Mutant delta8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids |
US8026089B2 (en) | 2006-12-07 | 2011-09-27 | E.I. Du Pont De Nemours And Company | Mutant Δ8 desaturase genes engineered by targeted mutagenesis and their use in making polyunsaturated fatty acids |
US8389808B2 (en) | 2007-02-12 | 2013-03-05 | E.I. Du Pont De Nemours And Company | Production of arachidonic acid in oilseed plants |
US8013215B2 (en) | 2007-02-12 | 2011-09-06 | E.I. Du Pont De Nemours And Company | Production of arachidonic acid in oilseed plants |
EP2441842A1 (en) | 2007-02-12 | 2012-04-18 | E. I. du Pont de Nemours and Company | Production of arachidonic acid in oilseed plants |
EP2441843A1 (en) | 2007-02-12 | 2012-04-18 | E. I. du Pont de Nemours and Company | Production of arachidonic acid in oilseed plants |
US8828690B2 (en) | 2007-04-03 | 2014-09-09 | E I Du Pont De Nemours And Company | Multizymes comprising delta-9 elongase and delta-8 desaturase and their use in making polyunsaturated fatty acids |
US7790156B2 (en) * | 2007-04-10 | 2010-09-07 | E. I. Du Pont De Nemours And Company | Δ-8 desaturases and their use in making polyunsaturated fatty acids |
WO2008124806A2 (en) | 2007-04-10 | 2008-10-16 | E. I. Du Pont De Nemours And Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
US8338152B2 (en) | 2007-04-10 | 2012-12-25 | E. I. Du Pont De Nemours And Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
US8188338B2 (en) | 2007-04-10 | 2012-05-29 | E. I. Du Pont De Nemours And Company | Delta-8 desaturases and their use in making polyunsaturated fatty acids |
WO2008128240A1 (en) | 2007-04-16 | 2008-10-23 | E. I. Du Pont De Nemours And Company | Delta 9 elongases and their use in making polyunsaturated fatty acids |
WO2008128241A1 (en) | 2007-04-16 | 2008-10-23 | E. I. Du Pont De Nemours And Company | Delta 9 elongases and their use in making polyunsaturated fatty acids |
WO2008137532A1 (en) | 2007-05-03 | 2008-11-13 | E. I. Du Pont De Nemours And Company | Delta-5 desaturases and their use in making polyunsaturated fatty acids |
EP2471928A1 (en) | 2007-05-03 | 2012-07-04 | E. I. du Pont de Nemours and Company | Method of obtaining oi comprising polyunsaturated fatty acids from transgenic seeds comprising delta-5 desaturases |
WO2008137516A1 (en) * | 2007-05-03 | 2008-11-13 | E.I. Du Pont De Nemours And Company | Delta-5 desaturases and their use in making polyunsaturated fatty acids |
US8957280B2 (en) | 2007-05-03 | 2015-02-17 | E. I. Du Pont De Nemours And Company | Delta-5 desaturases and their use in making polyunsaturated fatty acids |
US8399736B2 (en) | 2008-05-23 | 2013-03-19 | E.I. Du Pont De Nemours And Company | DGAT genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
EP2620501A2 (en) | 2008-05-23 | 2013-07-31 | E. I. du Pont de Nemours and Company | DGAT genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
US9790514B2 (en) | 2008-05-23 | 2017-10-17 | E I Du Pont De Nemours And Company | DGAT genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
US9187736B2 (en) | 2008-05-23 | 2015-11-17 | E I Du Pont De Nemours And Company | DGAT genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
US8153859B2 (en) | 2008-05-23 | 2012-04-10 | E.I. Du Pont De Nemours And Company | DGAT genes from oleaginous organisms for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
US8597931B2 (en) | 2008-07-11 | 2013-12-03 | Institut National De La Recherche Agronomique (Inra) | Mutant yeast strains capable of accumulating a large quantity of lipids |
WO2012001144A1 (en) | 2010-07-01 | 2012-01-05 | Institut National De La Recherche Agronomique | Optimization of lipid synthesis and accretion |
WO2012027698A1 (en) | 2010-08-26 | 2012-03-01 | E.I. Du Pont De Nemours And Company | Mutant hpgg motif and hdash motif delta-5 desaturases and their use in making polyunsaturated fatty acids |
WO2015189352A1 (en) | 2014-06-11 | 2015-12-17 | Institut National De La Recherche Agronomique | Improved lipid accumulation in yarrowia lipolytica strains by overexpression of hexokinase and new strains thereof |
US10760089B2 (en) | 2014-11-14 | 2020-09-01 | Basf Plant Science Company Gmbh | Materials and methods for increasing the tocopherol content in seed oil |
US10829775B2 (en) | 2014-11-14 | 2020-11-10 | Basf Plant Science Company Gmbh | Materials and methods for increasing the tocopherol content in seed oil |
US11033593B2 (en) | 2014-11-14 | 2021-06-15 | Basf Plant Science Company Gmbh | Brassica events LBFLFK and LBFDAU and methods for detection thereof |
US11260095B2 (en) | 2014-11-14 | 2022-03-01 | Basf Plant Science Company Gmbh | Modification of plant lipids containing PUFAs |
US11484560B2 (en) | 2014-11-14 | 2022-11-01 | Basf Plant Science Company Gmbh | Stabilising fatty acid compositions |
EP4151733A1 (en) | 2014-11-14 | 2023-03-22 | BASF Plant Science Company GmbH | Modification of plant lipids containing pufas |
US11613761B1 (en) | 2014-11-14 | 2023-03-28 | Bioriginal Food & Science Corporation | Materials and methods for PUFA production, and PUFA-containing compositions |
US11771728B2 (en) | 2014-11-14 | 2023-10-03 | Basf Plant Science Company Gmbh | Materials and methods for increasing the tocopherol content in seed oil |
US11813302B2 (en) | 2014-11-14 | 2023-11-14 | Basf Plant Science Company Gmbh | Brassica events LBFLFK and LBFDAU and methods for detection thereof |
US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
US12098146B2 (en) | 2019-01-24 | 2024-09-24 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2568624C (en) | 2014-03-25 |
US7256033B2 (en) | 2007-08-14 |
US20060195939A1 (en) | 2006-08-31 |
AU2005267202B2 (en) | 2011-10-27 |
EP1758991B1 (en) | 2013-01-16 |
US20050287652A1 (en) | 2005-12-29 |
WO2006012326A1 (en) | 2006-02-02 |
US7550651B2 (en) | 2009-06-23 |
AU2005267202A1 (en) | 2006-02-02 |
EP1758991A1 (en) | 2007-03-07 |
CA2568624A1 (en) | 2006-02-02 |
BRPI0512481A (en) | 2008-03-11 |
US20090264666A1 (en) | 2009-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2005267202B2 (en) | Delta-8 desaturase and its use in making polyunsaturated fatty acids | |
US9150874B2 (en) | Delta-9 elongases and their use in making polyunsaturated fatty acids | |
US8470571B2 (en) | Delta-8 desaturase and its use in making polyunsaturated fatty acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005267202 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2568624 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2005267202 Country of ref document: AU Date of ref document: 20050624 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005267202 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2005768249 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005768249 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005768249 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0512481 Country of ref document: BR |